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ABSTRACT
The purpose of this study was to categorize aberrant metabolic function in diabetic offspring
(FH+). This study examined metabolic flexibility (MF), and changes in fasting blood-glucose
concentrations and markers of lipotoxicity with resistance training in college age FH+ and FH-.
Results are significant at p = 0.05. MF testing indicate no baseline differences in RMR, VO2,
REE, fat or CHO use were noted between T2D, FH+, or FH-. Passive stretching caused
increased metabolism overall, however the T2D group temporarily displayed increased CHO use
during passive stretching, which quickly returned to pre-stretched levels during recovery as
compared with FH-. Both T2D and FH+ display impaired MF as compared with FH- via indirect
calorimetry as noted by the change in RER. With training, changes in glucose: lactate ratios
were no different between groups, but increased immediately after exercise with training, and
decreased at five and ten minutes post-exercise with training. Lastly, there were no differences
between FH- and FH+ in pre-training strength, BMI, or in markers measured in plasma before or
after exercise. Strength increased from pre to post training similarly. However, changes in NEFA
and insulin were noted in weight loss subjects vs non-weight loss. Negative correlations exist
between weight loss and: TG, NEFA, insulin and HOMA, and strength, and positive correlations
with blood glucose AUC.
Though there are differences metabolic flexibility and recovery kinetics between groups with
and without a family history of diabetes, this study does not reveal any such differences in
glucoregulatory function, or markers of lipotoxicity. Resistance training did not affect FH+
differently than FH-, however there were differences in these markers when groups were recategorized by weight loss. We were unable to isolate specific factors likely to contribute to the
development of IR or T2D within the confines of the current study. However, further research,
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such as lipid tracers and MRI studies are needed to determine factors leading to more aberrant
metabolic function in order to better understand what factors lead to the development of IR and
T2D.
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CHAPTER 1: INTRODUCTION
Diabetes is a metabolic disorder characterized by reduced ability to maintain healthy bloodglucose levels. Type-2 diabetes (T2D) is the fastest growing worldwide health pandemic[1, 2],
caused in large part by an imbalance of over-feeding and physical inactivity (positive energy
balance) leading to obesity [3]. The key deficiency in T2D is the inability to maintain proper
blood-glucose levels, and an important aspect of blood-glucose regulation is insulin’s ability to
sufficiently stimulate glucose transport into the muscle cells. This is done via insulin-stimulated
glucose transport (GLUT4) protein translocation from within the cell to the cell membrane [2, 4,
5]. Though there are several important glucose transporters that play a role, GLUT4 is the only
insulin-stimulated glucose transporter. In healthy conditions, insulin stimulates a cascade of
events within the muscle cell leading to the translocation of GLUT4 from within the cell to the
membrane, allowing it to transport glucose from the blood to within the muscle. If this process is
interrupted, blood-glucose levels increase.
Preceding elevated blood-glucose is increased insulin production in early stages, followed by
decreased production in more advanced diabetes when the pancreatic islet cells become damaged
as a result of advanced diabetes [2, 6].Several metabolic factors including lipotoxicity and
oxidative stress have been identified as major contributors leading to this condition. This reduced
ability of insulin to stimulate GLUT4 translocation is called insulin resistance (IR), which
ultimately results in the decline of glucoregulatory function in diabetes. The combination of
increased lipid and low oxidative capacity are key features in the development of muscular IR
[7-9]. Smaller and fewer mitochondria, in combination with reduced PGC1-α (transcriptional
factor for mitochondrial biogenesis) in muscle cells translate to lower ATP synthesis in diabetics
and first-degree relatives [10] leading to reduced capacity of insulin to properly dispose of blood1

glucose. Thus, mitochondrial dysfunction and metabolic inflexibility (defined as the impaired
capacity to increase fat oxidation upon increased fatty acid availability or to switch between fat
and glucose as the primary fuel source after a meal [11]) are considered major aspects of lipid
accumulation, and IR [12]. This reduction in metabolic flexibility further exacerbates the initial
lipotoxicity. Consequently, the development and progression of IR by lipotoxicity-related factors
has been the primary culprit in the development of T2D, and hence is the focus of much
research.
Despite extensive research in the field of IR, the progression of this epidemic still increases.
Current research has focused on improving glucose regulation and reducing IR in T2D.
However, in order to prevent T2D from developing, mechanisms responsible for the initial
development of IR must be revealed. Recent investigations of the possible initial causes of IR
have indicated that factors from lipotoxicity may be responsible for the development of oxidative
stress and inflammation- all common co-morbidities in T2D. Therefore, a logical next step in
studying T2D is to focus on lipotoxicity and the development of IR at its earliest stages.
Lipotoxicity refers to an overabundance of fat in blood or other tissues leading to pathologic
conditions, such as mitochondrial dysfunction and metabolic inflexibility in diabetes [13]. With
obesity comes an overabundance of stored adipose tissue in visceral and subcutaneous storage
depots. Increased triglyceride storage in these cells leads to an increased production of nonesterified fatty acids (NEFA) which aggravates insulin resistance in skeletal muscle [14] and are
often associated with increased intramyocellular triglyceride (IMCT) storage. The underlying
mechanisms whereby lipotoxicity causes decreased insulin sensitivity are unclear but appear to
involve elevated circulating (triglycerides, NEFA) and stored (IMCT) lipids acting directly on
the insulin-signaling pathway, and involve stimulation by mitochondrial dysfunction- both
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leading to serine phosphorylation on the insulin receptor substrates 1 and 2 (IRS1-2) of GLUT4
protein.
Elevated IMCT have long been associated with IR and oxidative stress [15]. However, recent
evidence suggests it is not the mere presence of IMCT that causes IR, but more likely that IMCT
are either a symptom of the mitochondria’s inability to oxidize fat at the pace at which it
becomes available (fat supply outpaces oxidation leading to a positive energy balance) [16], or
excess reactive oxygen species (ROS) produced by the mitochondria due to mitochondrial
dysfunction and/or elevated β-oxidation interact with the neighboring IMCT to cause oxidative
damage to the lipid (peroxidation). This process leads to increased IR [17] and an accumulation
of isoprostanes, like 4-HNE. Additionally, adipose tissue itself is known to go beyond fat storage
and serve as an endocrine organ producing substances that cause serine phosphorylation of IRS12, like interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), leptin and resistin, any of
which can also lead to insulin resistance.
Besides IMCT and adipokines leading to IR, circulating fat has been shown to be elevated in
obesity and IR states [18], and may be partially responsible for the development of IR. One
possibility is that the mitochondria are unable to maintain high enough levels of β-oxidation in
the presence of increased lipid concentrations due to decreased physical activity, which leads to
increased NEFA [3]. Recent data suggest that elevated levels of circulating NEFA, in
combination with reduced metabolic activity may be major contributors to both IR and agents
antagonistic to mitochondrial function, such as oxidative stress and inflammation, both of which
contribute to progression of diabetes [3]. NEFA have been shown to lead to increased production
of reactive lipids such as diacylglyceral (DAG), and results in the activation of protein kinase c
(PKC), which in turn activates the serine/threonine phosphorylation of IRS1-2 [13]. When the
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serine/threonine ends of IRS 1-2 are phosphorylated, the tyrosine end is inhibited from being
phosphorylated [19], which is essential for insulin-stimulated GLUT4 translocation.
Furthermore, an abundance of NEFA availability leads to increased mitochondrial selection of
lipid as substrate, competing with glycogen. Combined with decreased metabolism, this
increased lipid oxidation leads to increased production of ROS, and incomplete breakdown of
lipid in the mitochondria (acylcarnitine build-up).
In addition to the direct impact of circulating fat has on insulin resistance, elevated lipids lead
to increased fat oxidation and a subsequent accumulation of acetyl-CoA leading to increased
acylcarnitine levels. Even chain acylcarnitines containing up to 20 carbons accumulate in
response to incomplete fatty acid β-oxidation. In contrast, amino acid catabolism produces odd
chain-length species like C3 and C5–acylcarnitines, although C4– acylcarnitines can be derived
from either amino acid or fatty acid metabolism. Acetyl (C2)–carnitines are derived from
carbohydrate catabolism and from the ultimate product of β-oxidation, acetyl-CoA [20].
This rise in acetyl-CoA can exceed cellular energy requirements, and as a competitive
inhibitor of pyruvate dehydrogenase, effectively reduce the pyruvate dehydrogenase complex,
and glucose metabolism [11]. Furthermore, the subsequent increase in glucose-6-phosphate
accumulation within the cell leads to hexokinase inhibition, which results in a negative feedback
reducing glucose uptake. This reduction in glucose metabolism leads to less glucose uptake into
muscle cells, and a subsequent rise in blood-glucose. In addition, there is also a build-up of
malonyl-CoA seen in T2D [21-23]. These elevated concentrations of malonyl-CoA inhibit
palmitoyltransferase-1, the rate limiting step in the transport of long-chain fatty acids into the
mitochondria [21]. This leads to a build-up of acylcarnitines in the muscle cell, causing lipid
peroxidation of the mitochondria and increasing mitochondrial dysfunction [24].
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To further complicate the diabetic profile, a build-up of Acetyl-CoA inhibits β-oxidation.
However, with the surplus of lipid available to metabolize, the Co-A on Acyl-CoA interacts with
carnitine so that the fat molecule can be transported into the mitochondria for β-oxidation. With
increased β-oxidation also comes more ROS being produced, which can lead to mitochondrial
damage and dysfunction. The combination of increased acylcarnitine production and ROS, and
reduced β-oxidation lead to a further build-up of acylcarnitines, thus perpetuating a cycle.
In addition to the above complications caused by elevated acetyl-CoA, there is also an
inherent proton leak from the mitochondria that is associated with beta-oxidation [25]. This
proton leak reacts with molecular oxygen to form superoxide (SO), which is an extremely potent
free-radical and the first ROS molecule formed in the oxidative process. From there, SO can
react with several protective molecules like superoxide dismutase (SOD) or iron to form the
hydroxyl radical (OH-), or the less reactive hydrogen peroxide (H2O2). These radicals are further
neutralized by subsequent endogenous antioxidants like glutathione peroxidase (GPx) or
Catylase (CAT). When ROS production is no longer effectively neutralized by endogenous
antioxidants (like SOD, GPx, or CAT), a state called oxidative stress exists. Oxidative stress can
lead to cellular damage (oxidative damage) causing increased IR, or the production of c-Jun
Kinase (JNK) which can either inhibit glucose transport by phosphorylating the serine/threonine
ends of the IRS1-2, or cause further mitochondrial dysfunction [25]. Oxidative damage can be
quantified from either protein (protein carbonyl) or lipid (8-isoprostane, 4-NHE).
It is well-established that exercise improves glucose tolerance. Endurance training
specifically has been shown to improve insulin sensitivity by up-regulating GLUT4 expression,
improve nitric oxide-mediated skeletal muscle blood flow [26], reduce hepatic glucose output
[27], and normalize blood-lipids [28]. Resistance training on the other hand not only has similar
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consecutive exercise effects as aerobic, but also is associated with significant skeletal muscle
mass increases, thereby improving whole-body glucoregulatory function [29]. Regardless of
exercise type, total energy expenditure has been shown to be the biggest determinant of exerciseinduced changes in glucose homeostasis [30-32]. Given these considerations, perhaps the best
exercise option for improving glucoregulatory function is to incorporate both aerobic and
resistance training to burn more calories, such as a circuit training regime designed to increase
strength, burn calories, and keep heart rate elevated.


Conclusion
In light of the increasing prevalence of T2D, it is important for research to focus not only on

treatment of diabetes but also prevention and halting its progression at its earliest stages.
Interestingly, IR individuals with a family history of diabetes (FH+) may be an ideal group in
which to study the initial development of IR because they have been shown to be at
approximately 40% higher risk for developing T2D than those with no family history (FH-) [33,
34], and have impaired hexokinase II activity similar to T2D [19]. The benefit of studying IR in
this population is that they have not yet developed many of the confounding factors that may
contribute to the development of T2D like glucotoxicity or obesity, yet FH+ display a 50%
reduction in the rate of insulin-stimulated whole-body glucose metabolism due to decreased
muscle glycogen syntheses rates [33], indicating that the pathogenesis of IR can be examined at
its earliest time points [35]. In addition, there is a lack of understanding concerning the
pathologic connection shared with T2D that pre-disposes them to be more likely to develop this
disease in the future. Recent data suggests that impaired metabolic flexibility (MF) similarly
affects FH+ and T2D, indicating that lipotoxicity may be an early contributing factor for the
development of IR in the FH+ population [3, 15].

6

In exploring the metabolic profile of the FH+ population, a multi-factor approach is needed
to establish a more accurate understanding of what pathologic link this group shares with T2D.
For example, with IR often comes mitochondrial dysfunction leading to metabolic inflexibility.
However, this has yet to be established in the FH+ group without documented IR existing. It
also may be possible to alter glucoregulatory function of prostaglandins via acute aspirin
ingestion in this population. It is possible that lipid-induced development of chronic
inflammation leads to IR, and inhibition via NSAIDs could help reverse this. Furthermore,
exercise interventions have been shown to successfully decrease IR and aid in glucoregulatory
function in T2D. However, such an intervention may also alter glucoregulatory function in
apparently healthy FH+.
Chapter 1 introduced the topic of T2D and lipotoxicity. Several characteristics of IR are
highlighted as seen in T2D, and FH+ are introduced as a possible early IR population for further
study. In Chapter 2, metabolic flexibility will be compared between FH-, FH+ and T2D. Chapter
3 will examine whether acute prostaglandin inhibition affects OGTT by using 975 mg of aspirin.
In chapter 4, the effects of seven weeks of resistance training on fasting blood-glucose in
controls and FH+ will be examined. Finally, chapter 5 will include an in-depth examination of
biochemical markers of lipotoxicity in both controls and FH+, and if resistance training can
affect these markers.
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CHAPTER 2: DEVIATIONS IN METABOLIC FUNCTION IN HEALTHY DIABETIC
OFFSPRING: DEVIATIONS IN METABOLIC FLEXIBILITY
Introduction
Type-2 diabetes (T2D) is a pandemic disease [36] characterized by insulin resistance (IR),
which develops one to two decades before the onset of type-2 diabetes (T2D), [34, 37] and is the
best predictor for future development of this disease [2, 37]. Since IR is related to several comorbidities like elevated lipid levels, loss of metabolic flexibility (MF) and impaired
glucoregulatory function, much attention has been given to studying these co-morbidities.
IR subjects not only display elevated fasting β-oxidation, but also impaired MF, which is
characterized by impaired ability to switch to carbohydrate as substrate from the fasted-to-fed
transition [16]. Several factors are likely to contribute to the development of this condition,
including decreased hexokinase activity and peroxisome proliferator-activated receptor gamma
coactivator 1 (PGC1) expression, which are both seen in T2D [38]. In addition, disturbances of
free-fatty acid/nonesterified fatty acid (FFA/NEFA) metabolism, elevated basal rate of lipolysis,
and impaired suppression of plasma NEFA concentration by insulin, are also associated with IR
and reduced MF [39-41]. Although there is a strong indication that these factors are related to
MF, with so many co-morbidities and additional confounding factors (like obesity and impaired
glucoregulatory function) often present in T2D patients, it is difficult to distinguish which factor
may be the initial trigger for developing IR.
Interestingly, IR individuals with a positive family history of diabetes (FH+) may be an ideal
group in which to study the initial development of diabetes and its earliest co-morbidities for
several reasons. These individuals have been shown to be at approximately 40% higher risk for
developing T2D than those with no family history (FH-) [33, 34], and have impaired hexokinase
II activity and PCG1 expression similar to T2D [19, 38] which may lead to decreased expression
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of nuclear respiratory factor 1 (NRF-1) [38]. The benefit of studying IR in this population is that
these individuals often have not yet developed many of the confounding factors that may
contribute to the development of T2D, like glucotoxicity or obesity, yet they display a 50%
reduction in the rate of insulin-stimulated whole-body glucose metabolism due to decreased
muscle glycogen synthesis rates [33]. This suggests that the pathogenesis of T2D in the FH+
population can be examined at its earliest time points [35]. To date, much of the research on FH+
has been in sedentary, IR FH+ only, making it difficult to isolate the pathologic connection
shared between FH+ and T2D leading to the development of IR and diabetes [42, 43].
Furthermore, Galgani suggests that assessment of MF at rest is insufficient to detect deficiencies
in fat metabolism, as the demand for fat oxidation at rest is minimal [44]
Therefore, the purpose of the current study was to determine whether a decline of MF exists
in a young, active FH+ population with normal glucoregulatory function with traditional glucose
loading, and with separate metabolic stimulus, and to compare the MF of active FH- with that of
active FH+ and T2D. Data from the present study could potentially aid in development of
effective screening tools and interventions to prevent T2D progression in the FH+ population.
It was hypothesized that that FH- are highly metabolically flexible as measured by changes in
RER after an oral glucose load. Furthermore, FH+ and T2D, populations shown to have impaired
hexokinase and PGC-1 [19, 38], are likely to display increasing metabolic inflexibility with
glucose load. In addition, passive stretching was expected to illicit a more substantial shift in
substrate use in FH- as compared with FH+ and T2D due to the increased metabolic demands
from mild exercise [44] than that of traditional MF testing via glucose loading.
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Methods


Subjects.
Thirty-seven subjects were recruited from the Baton Rouge area using local advertisements

and word of mouth to participate in one morning of fasting metabolic testing. FH+ was
categorized as being a 1st or 2nd degree relative of a person with T2D. The subject population
consisted of 10 healthy, active controls with no family history (FH-) of diabetes, 16 FH+, and 11
T2D subjects. Age, gender, BMI, and activity were matched between FH+ and FH-. The
purpose, potential risks and benefits of participation in the study were fully explained to each
participant before written consent was obtained prior to testing. The study was approved by the
Ethical Committee of Louisiana State University (LSU office of IRB). All FH+ and FH- subjects
had normal fasting blood-glucose prior to testing using a hand-held finger-prick glucose meter.
Additional inclusion criteria for FH+ and FH- groups were no overt disease, including but not
limited to cardiovascular disease, hypertension, impaired glucose tolerance (IGT) kidney or renal
disease, are physically active, blood-glucose concentrations under 10 mmol/L (180 mg/dL) an
hour after glucose loading, BMI between 18.5-24.9 kg per m2, and not taking prescription
medication other than oral contraceptives. T2D subjects had no BMI exclusions, and were
allowed to take prescribed glucose-lowering medication. A physical activity questionnaire was
completed prior to participation in the study to determine eligibility. Subject characteristics are
summarized in Table 2.1.


Research Design.
The study consisted of a single session with three components: 1) assessment of resting

metabolic rate (RMR), 2) assessment of response to a low-intensity metabolic stimulus (passive

13

Table 2.1 Subject characteristics: Age (years), Height (cm), Weight (cm), and Body Surface
Area (BSA). Mean ± SE.

Age (years)
Height (cm)
Weight (kg)
BSA

FH+
24 ± 1.1
170.5 ± 2.9
70.6 ± 3.2
1.81 ± .06

FH23.1 ± 2.0
173.8 ± 1.9
76.0 ± 3.2
1.90 ± .05
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T2D
*37.7 ± 6.1
170.0 ± 3.3
*88.4 ± 6.8
1.98 ± .08

P
0.01
NS
.037
NS

stretching), and 3) assessment of physiologic responses to an oral glucose load while under a
metabolic canopy, including MF.


RMR Assessment.
Participants reported to the lab to begin the study at 7:45 in the morning after a ten-hour fast.

Participant’s height and weight were measured and they were asked to fill out an activity
questionnaire; then at 8:00 AM, they were placed in the supine position for thirty minutes prior
to RMR testing. During this time, fasting blood-glucose were collected via finger prick and
measured using an AccuChek CompactPlus glucose monitor (Indianapolis, IN), a precise and
reliable means of assessing blood-glucose [45]. After the initial thirty minute rest period, a
plastic canopy connected to a metabolic system was placed over the subject’s head to collect and
analyze resting expired gases for 50 minutes. This time period included a 20-minute stabilization
period followed by 30 minutes of data collection with continual monitoring to ensure
wakefulness. For one subject, an extra ten minutes of stabilization time was required to recalibrate the metabolic cart. Figure 2.1 shows a timeline for the test morning. Expired gas was
analyzed using a Moxus Max-II Metabolic System (AEI Metabolic Systems, version 2.7.01,
Naperville, IL) which was calibrated by a trained technician per manufacturer’s instructions
using two gas mixtures with known O2 and CO2 composition before each test. RMR values were
monitored, and after twenty minutes of stable RMR data were collected, the subsequent thirty
minutes of RMR were recorded, averaged, and used for analysis as fasting oxygen kinetics at rest
(Figure 2.1)


Metabolic Response to Passive Stretch.
At 9:22 AM, immediately following the initial RMR, another blood-glucose assessment was

conducted via finger prick, and twenty minutes of passive stretching was performed while the
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Figure 2.1 Timeline of study test morning.
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participants were resting under the metabolic canopy. Passive stretching was subsequently
used as a mild metabolic stimulus, and was conducted by a lab technician while gases were
collected under the RMR canopy to determine substrate utilization. Each participant indicated
attainment of appropriate muscular tension by lifting one finger. When the appropriate tension
was reached as indicated by the participants, the stretch was held for twenty seconds, and then
repeated after a ten second break. Muscles stretched included gastrocnemius, hamstring,
quadriceps, hip abductors, gluteal muscles, pectorals major and minor, and forearms. RMR data
were collected up to five minutes post-stretching to measure oxygen recovery kinetics as oxygen
and substrate selection changes during recovery, and then post-recovery determination of blood
glucose was again conducted via finger prick and glucometer analysis. Since the metabolic
stimulus from passive stretching was considered constant for the entire 20-minutes, peak
stretching values consisted of average values during the last five minutes of passive stretching.
Post-stretching recovery values consisted of the last minute of the five-minute recovery period
(Figure 2.1).


Metabolic Flexibility Assessment.
Following stretching and recovery, participants were given a ten minute break before

beginning the MF testing using an oral glucose dose rather than insulin clamp as suggested by
previous studies [43, 46, 47]. While still fasting, each participant consumed a solution of 50g
glucose dissolved in 10oz of water. Each glucose beverage was consumed within two minutes,
and then the participants went back to the supine position with the metabolic canopy over their
heads for another 60 minutes with continual monitoring to ensure wakefulness. Blood-glucose
was analyzed via finger prick and glurcomet every fifteen minutes for 1-hour to determine bloodglucose responses to the oral glucose load, and expired gas was continuously measured for 60-
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minutes similar to studies examining postprandial hyperglycemia, a well-recognized risk-factor
of T2D [48, 49].


Analyses.
RMR analysis was computed in part by Moxus software, including VO2 (ml/kg/min), VCO2

(ml/kg/min), RER, VEO2 (l/ml), VECO2 (l/ml), as well as VO2 and VCO2 adjusted for
BSA(ml/m2). Additional determinations of resting metabolic rate (RMR) were calculated with
consideration of protein metabolism using the abbreviated formulas of Weir [50]. Fat (g), Fat
(kcal) and CHO (kcal) were calculated using equations from additional reviews, and MF were
calculated in Microsoft Excel 2007 with the following equations:
RMR = (3.9 x VO2 L/min) + (1.1 x VCO2 L/min) [50]
Fat g = (1.67 x VO2 L/kg) – 1.67 x VCO2 L/kg) [51]
Fat kcal = 9 x (Fat g), [51]
CHO kcal = REE – Fat kcal
CHO kcal = 4.58 VO2 L/kg – 3.23 VCO2 L/kg [51]
MF = (RER stimulus) – (RER rest) [52]
Where stimulus was average RER every 30 seconds during the hour following glucose
loading.
All statistics were calculated using SPSS 15 (Somers, NY). Subject characteristics were
analyzed using 1-way ANOVA. Variables such as pre stretch RMR, blood-glucose concentration
after glucose loading, or MF area under the curve (AUC) differences between groups were
calculated using a 1-way ANOVA with Tukey post-hoc comparisons. Changes pre to poststretching, or pre to post blood-glucose concentrations were analyzed using repeated measures
with LSD post-hoc comparisons to determine magnitude of change differences between groups.
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Pearson product moment correlation was used to determine relationship between variables. All
comparisons were considered significant at the alpha level p = 0.05.
Results
T2D were characterized by higher weight, BMI, and age than FH+ or FH-, and had
significantly higher fasting blood-glucose than the other groups (85.1 ± 1.8, 91.2 ± 2.9, and
108.9 ± 7.3 mg/dl FH-, FH+, T2D mean ± SE, respectively). No significant differences in resting
metabolism were noted between any of the groups (Table 2.2).
Relative VO2 significantly increased with stretching in FH-, FH+, and T2D (12.3 ± 2.2, 11.8
± 2.4, and 18.3 ± 2.3 % respectively, p < 0.001) with no significant differences between groups
(p = 0.83). CHO use significantly increased overall with stretching (p = 0.01) with a trend of
more increased CHO use for FH- to FH+ and T2D (0.034 ± 0.01, 0.127 ± 0.01, 0.331 ± 0.01
kcal/min respectively; p = 0.17) (Figure 2.2). \ However, a rapid return of CHO use from peak
stretching to the last minute of the 5-minute recovery was noted overall (0.29 ± 0.01, 0.10 ±
0.01, -0.29 ±0.02, FH-, FH+, T2D respectively, p = 0.002) with significantly greater change in
T2D than FH- (p = 0.029). FH+ was not significantly different than either T2D (p = 0.11), or
FH- (p = 0.39) (Figure 2.3).
Additionally, blood-glucose dropped from pre to post stretching overall (p = .03) with
significantly greater blood-glucose decline in T2D than both other groups (p = .001). Increases in
overall fat use with stretching were non-significant (p = .29). Changes in RER with stretching or
recovery were not significantly different between groups (p = .16). Pre-stretching, peakstretching, and post-recovery values are shown in Table 2.2 (above).
Blood-glucose concentrations were 30% higher for T2D than FH- or FH+ (Figure 2.4) within
one hour of glucose-load. Resting energy expenditure (REE) and relative VO2 remained constan
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Table 2.2 Mean ± SE for fasting: Relative VO2, Respiratory exchange ratio (RER), Blood-glucose (BG), carbohydrates (CHO) and fat
used at rest for FH-, FH+, and T2D.

Pre-Stretching
FHFH+
VO2 (ml/kg/min) 3.17 ± .29
2.89 ± .16
RER
.78 ± .02
.78 ± .02
BG (mg/dl)
85.1 ± 1.8
91.2 ± 2.9
CHO (kcal/min)
.30 ± .07
.31 ± .06
Fat (kcal/min)
.75 ± .08
.72 ± .07
a
Significant from previous measurement at 0.05
b
Change significantly different than FH- at 0.05
c

T2D
2.68 ± .32
.76 ± .02
bc
108.9 ±
7.3
.26 ± .07
.79 ± .08

Peak Stretching
FHFH+
3.56 ± .22
3.23 ± .24
.78 ± .01
.79 ± .01
a
.33 ± .05
.86 ± .11

Change significantly different than FH+ at 0.05
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a
.44 ± .07
.79 ± .09

T2D
3.17 ± .3
.79 ± .03
a
.59 ± .19
.75 ± .10

Post-Recovery
FHFH+
3.45 ± .23
3.24 ± .13
.8 ± .01
.82 ± .02
a

82.3 ± 2.8
.62 ± .14
a
.70 ± .04

a

84.2 ± 1.6
.54 ± .06
a
.67 ± .06

T2D
2.49 ± .44
.73 ± .05
abc

102.3 ± 5.1
.30 ± .08
a
.63 ± .10

b

0.4

*

0.35
0.3

kcal/min

0.25
0.2

*

*

0.15
0.1

Fat
CHO

0.05
0
-0.05
-0.1

FH-

FH+

**

T2D

Group

* Significant change from pre to peak

** Change significantly greater than other groups (p = .001)
Figure 2.2 Change in substrate use from rest to peak passive stretching showing significant
increase in CHO use in overall group, with more significant changes in T2D than FH- or FH+ (p
= .001). Mean ± SE.
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0.2
0.15

Energy Expenditure
(kcal/min)

0.1
0.05
0
-0.05
-0.1

*

*

*

CHO
Fat

-0.15
-0.2
-0.25
-0.3

**
FH-

*T2D

FH+
Group

Figure 2.3 Changes in Fat and CHO kcal/min from peak stretching to recovery. Significant drop
in Fat use from peak stretch to recovery, and significantly less CHO use in T2D than FH-. *
Significant change from pre to post (p = .01); **Change significantly greater than other groups (p =
.001). Mean ± SE.
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throughout the 1-hour post glucose loading. However, changes in kcal/min of both fat and
CHO differed significantly between T2D and FH- from rest to peak passive stretching and
subsequent recovery (Figures 2.2 and 2.3). Also, MF AUC was significantly higher in FH- than
either FH+ or T2D, with no differences between FH+ and T2D (Figure 2.5).
Discussion
No baseline differences in RMR, VO2, REE, fat or CHO use were noted between T2D, FH+,
or FH-. As expected, fasting blood-glucose was significantly higher in T2D than other groups
with no difference in CHO oxidation. Contrary to previous studies [53], fasting whole-body fat
oxidation was not significantly higher at rest in T2D than FH- in this study. In support of the
secondary hypotheses, FH+ displayed impaired substrate shifts between that of FH- and T2D as
noted by the lack of significant differences between FH+ and either of the other two groups.
Passive stretching caused increased metabolism overall, however the T2D group temporarily
displayed increased CHO use during passive stretching, which quickly returned to pre-stretched
levels during recovery as compared with FH-. The overall hypothesis of progressively increased
metabolic inflexibility in FH+ and T2D was substantiated by the data. FH+ and T2D displayed
similar impairments in MF as compared with FH- via indirect calorimetry as noted by the change
in RER. Lastly, 60-minute blood glucose concentrations AUC for T2D were significantly higher
than FH+ or FH-, which is similar to previous findings of postprandial hyperglycemia [54]
indicating high postprandial hyperglycemia in T2D with mixed-meal and oral glucose load.


Stretching
Passive stretching significantly increased VO2 and RER which is consistent with previous

data indicating stretching not only increases metabolism, but also CHO use [27]. For example,
studies have shown that a passively stretched in vitro muscle exhibited increased heat production
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Figure 2.4 1-hour blood-glucose concentrations post glucose-loading indicate significantly worse
glucoregulatory function in T2D than FH+ or FH- (p = .002). Mean ± SE.
*Significantly different than FH+ and T2D.
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Figure 2.5 Mean ± SE for Metabolic Flexibility: (RER during glucose load) – (RER Fasting)
Area under the curve. *Significantly different than FH- (P = .002).
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.
[55] and increased oxygen consumption [56] [57] similar to our findings. In other related
studies, passive stretching increased glycogen breakdown [58], increased lactic acid production
[57], and decreased phosphocreatine concentrations [59]
Since increased metabolic activity is related to increased activation of the AMPK GLUT 4
activation pathway [60] [61] [62], it is plausible that the increased metabolic activity
accompanying passive muscle stretching could activate GLUT 4 in the stretched muscles [63]
which would help explain increased CHO use we exhibited with stretching in the present study
(Figure 2.3).
Although there was a significant increase in CHO use with stretching, group differences were
not found. It should be noted that in previous studies, similar substrate utilization was observed
between T2D and controls while T2D displayed significantly greater NEFA turnover [64-66].
Similar to previous findings in T2D [53, 64, 67-69], blood glucose declined significantly after
passive stretching during the recovery period, however, the reductions were greater in T2D than
FH- or FH+, likely because of the higher starting point (p = 0.001). Interestingly, unlike the
previous studies, the metabolic stimulus used in the present study (passive stretching), stimulated
metabolism increases to a much less degree, indicating it may not be the magnitude of energy
expenditure that leads to reduced plasma glucose as much as the mere presence of a mechanical
stimulus. This is in accordance with previous findings of Hansen [70]. However, though bloodglucose appears to decrease more in T2D and FH+ than FH- (-2.8, -6.0, -6.6 FH-, FH+, T2D
respectively), no significant difference was reached with the absolute change from pre-stretching
to post-recovery between groups (p = 0.75). The fact that blood-glucose was lower across all
groups with stretching supports the idea that passive stretching activates non-insulin induced
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GLUT4 translocation which would support previous findings [53] indicating plasma glucose
declines with exercise in T2D at the same time as plasma insulin. Though our methods do not
specifically isolate glycogen use/turnover, it is interesting to note the increased CHO use occurs
simultaneously with reduction in blood-glucose, further supporting the contention of Morino and
Shulman [35] that glycogen turnover is affected by glucose transport. However, it was not
possible within the constraints of this study to determine a timeline for reduced blood-glucose vs.
increased CHO use with stretching, and thus it is also not possible to establish which one leads to
the other. However, in the current study, there was a significant correlation between decreased
blood-glucose and increased CHO use from pre to post-stretching overall (.385, p = .027),
showing a direct relationship between the two.
CHO use from peak stretch to recovery revealed a significantly greater drop in the T2D
group than FH- similar to Boon’s findings [53], but no significance between FH+ and either FHor T2D, indicating 1) though stretching causes up-regulation of CHO use and decreased bloodglucose concentration, greater CHO use from passive stretching are short-lived during recovery
for T2D subjects, and 2) FH+ subjects fell in between FH- and T2D for increased CHO use and
decreased blood-glucose changes. This indicates that though the FH+ subjects displayed no overt
signs of IR, and as young, non-obese, active individuals, they may be an ideal group to study the
earliest steps towards pathologic metabolic complications leading to IR. When considering
Boon’s findings, the similarities in post-stretching fat and CHO oxidation between T2D and FH+
may indicate increased plasma NEFA oxidation in a young, active FH+ population. However,
further research is needed for verification.
Our results of a single bout of passive stretching indicate reductions in blood-glucose levels
in T2D similar to other studies [71]. What is interesting to note in the present study is the more
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significant reduction of blood-glucose in the T2D group than FH-. Granted, the T2D had a
significantly higher fasting blood-glucose, which would indicate that greater reductions are more
likely. However, we also noted a larger drop in CHO use with this population than FH- or FH+
indicating that without a metabolic stimulus, T2D subjects are not as effective at using CHO
after stretching. These data suggest that stretching may be able to increase MF somewhat in
adverse populations; however, since the metabolic stimulus was so low, it is likely that a more
intense stimulation (e.g. walking) may increase post-exercise metabolic demands and thus
prolong the beneficial effects of increased metabolism. Although it has been established that
moderate to high exercise intensity aids glucoregulatory function [18, 70] the current data
suggests that even the least aggressive kind of exercise (passive stretching) may still have some
benefit. However, future work is needed to examine a possible dose-response to exercise: first, to
determine of the increased CHO use is related to the metabolic stimulus, and second, to
determine if the increased CHO use is further related to decreased blood-glucose. Future studies
are needed to better isolate the minimum dose (time, intensity, kcal, etc) needed to increase postexercise CHO use, and determine if oxygen kinetics and substrate selection are linked with
improved glucoregulatory function.
Though FH- displays significantly different CHO use than T2D with stretching, no
differences in increased CHO use were noted between FH+ and either the FH- or T2D group
with passive stretching. This possibly suggests that though the FH+ group is young, active, and
not overweight, their metabolic function may function somewhere inbetween healthy FH- and
T2D, and thus would be an ideal population to study the earliest progression of IR and metabolic
dysfunction.


Metabolic Flexibility
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Though IR was not assessed, the declining blood-glucose concentrations after glucose
loading revealed that FH- and FH+ groups had similar blood-glucose responses, and both were
significantly better than the T2D group. Given the age, BMI, activity level, and blood-glucose
responses of the FH+ group, it is unlikely that they suffered from insulin resistance.
It was expected that the T2D group would have more impaired glucoregulatory function and
metabolic flexibility than FH-, especially given the differences in age, weight, and diabetes
status. Furthermore, recent studies have indicated that 1st degree FH+ with IR also display
impaired MF. However, in the current study, 1st and 2nd degree FH+ displayed impaired MF
independent of IR. In addition, this group was not only age, BMI, and activity-matched with the
FH- group, but unlike previous studies [43], both groups were highly physically active (having
spent more than 5 hours per week in vigorous activity) as determined by an exercise
questionnaire. Thus, metabolic inflexibility in this group is a novel finding (Figure 2.6) given the
level of intensity and duration of physical activity for both groups. The degree of MF impairment
was not only significantly worse than FH-, but actually matched that of the T2D group. This
suggests that independent of favorable blood-glucose concentration responses to an oral glucose
load, or ideal fasting blood-glucose levels, FH+ and T2D are less able to effectively shift
substrate use after ingesting a glucose load than FH-. Previous studies that indicate that reduced
MF is likely due to declining disposal rate [72], or high fasting blood-glucose concentrations
[44], though in the current study stretching induced a reduction of blood-glucose concentration,
and both FH- and FH+ had similar fasting blood-glucose concentration. This would suggest that
other factors may affect MF, including genetics [73].
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Figure 2.6 Mean ± SE for RER (Top) and change in RER (metabolic flexibility) (Bottom) up to
1-hour post glucose load. *Significantly different than FH+ and T2D, p = 0.05.
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Factors that may contribute to the reduced MF in the FH+ group may include impaired fat
oxidation in the mitochondria, together with triglyceride fluxes from liver and intestine leading
to a build-up of IMCT and/or acylcarnitines [3, 11, 15, 44]. CD-36 expression is also often upregulated in IR, promoting increased fatty acid transport leading to competition with CHO as
substrate [11]. However, combined with the data illustrating no differences between groups in fat
oxidation in the 1-hour test, it seems unlikely that fatty acid uptake is a culprit in the reduction of
MF. However, it may be possible to employ the measure of CHO utilization after an oral glucose
load, or during and after exercise as a possible early indicator in the development of IR in at-risk
populations. It has also been shown that FH+ individuals have impaired hexokinase-II activity
as compared with controls [19]. This reduction could lead to decreased glyconeogenesis, thereby
reducing the cell’s glycogen stores and its ability to utilize CHO as substrate, and further limit
glucose-uptake.
The T2D group had a significantly greater decrease in fat oxidation with glucose stimulus
than FH-, with FH+ having no significant differences between either FH- or T2D. This indicates
that T2D are less able to shift from fat oxidation than FH-. This could be due to competitive
inhibition that fat oxidation elicits on glycolysis [11, 19, 44], the supply of fat outpacing energy
needs leading to partial breakdown of fat [3, 11], a build-up of lipid intermediates such as
diacylglyceral (DAG), or JNK [19], or effects of hormones such as leptin or resistin which are
produced by fat cells [74, 75]. However, with no such measurements performed in this study,
further research is needed to be able to specifically identify such factors inhibiting cellular shifts
in substrate utilization.
Though this study lacks the experimental design needed to elucidate alterations in use of
muscle-specific substrates, i.e. use of tracers or magnetic resonance spectroscopy, it does
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illustrate that MF can be measured in as little as one hour using standard indirect calorimetry
methods. Also, finger-prick blood-glucose data are not considered as accurate as running clinical
chemistry analysis of glucose on plasma. However, recent studies indicate that such testing can
be a precise and reliable means of assessing blood-glucose [45], especially with the practice of
duplicate testing used in the present study. Thus, the use of the Accu-check Compact Plus
appears to be a valid tool for blood-glucose measurements in this study. In addition, though there
was no control diet given in the present study, participants were in an 11-hour fasted state prior
to the glucose-load and MF assessment, which began over an hour after arrival. It has also been
reported that regulation of RQ/RER is the most important reason for administering a control diet
for MF testing [44]. Recent studies indicate in order for food quotient (FQ) to become equal to
respiratory quotient (RQ), it could take up to one week of regulated diet [44]. Therefore, the
importance of dietary regulation is to regulate FQ long enough so FQ equalizes with RQ in all
groups. Since some studies report higher fasting RQ/RER in T2D than controls, calculations of
reduced MF are skewed by a higher starting RQ [44]. However, in this study there were no
significant differences in fasting RER between any groups, making it less critical to control diet.
Lastly, the T2D group was significantly older than either the FH- or FH+ groups. However, the
purpose for including a T2D group for to establish a point of reference for advanced diabetes. As
such, FH+ displaying similar metabolic inflexibility to T2D, even with significant age
differences, is further evidence that having a family history of T2D is an important factor in
aberrant metabolic function.
The current study also included a large population of subjects with three strongly defined
populations. In addition, FH- and FH+ were matched for age, height, weight and activity level,
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and in spite of the closely matched groups, FH+ and T2D still exhibited reduced MF relative to
FH-.
Conclusion
Passive stretching leads to a short-lived increased CHO use in T2D, FH+, and FHpopulations with significant reductions in blood-glucose, especially in T2D. Fat use with
stretching remains similar throughout each group in spite of previously reported fat oxidation
differences in T2D [19, 44, 53].
An oral dose of glucose leads to increased CHO use in all groups, with significantly higher
CHO use in FH- than either FH+ or T2D. Furthermore, change in RER with oral glucose
(metabolic flexibility) is far greater in FH- than either FH+ or T2D, which exhibit equally
reduced MF as compared to FH-. Therefore, FH+ either with no IR, or low-level IR may be an
ideal group to study mechanisms that could potentially lead to the development of IR.
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CHAPTER 3: FASTING BLOOD-GLUCOSE CHANGES IN DIABETIC
OFFSPRING AND CONTROLS WITH SEVEN WEEKS OF RESISTANCE TRAINING
Introduction
Type-2 diabetes (T2D) is a pandemic disease [1] characterized by insulin resistance (IR),
which develops one to two decades before the onset of type-2 diabetes (T2D) [2, 3]. According
to WHO criteria, T2D is defined as having fasting plasma glucose equal or above 7.0 mm/L (126
mg/dL), or if 2 hours post 75 g oral glucose tolerance test (OGTT) plasma glucose concentration
rises equal or above 11.1 mmol/L (200 mg/dL) [4]. Exercise is the only treatment strategy that
consistently results in improved whole body and skeletal muscle oxidative capacity [5], however
there is debate over what kinds of exercise are most beneficial in treatment of T2D [6].
Interestingly, IR in persons with a family history of T2D (FH+) increases the likelihood of
developing T2D by 40% [2, 7], and is the best predictor for developing this disease in the future
for this population [3, 8]. Recent studies have indicated that FH+ with IR exhibit impaired
metabolic flexibility (MF) and/or impaired mitochondrial activity prior to developing T2D [911]. Interestingly, some studies also show impaired MF in FH+ without having IR ([12], Russell
et al., unpublished data). Recent studies suggest that impaired MF contributes to increasing
obesity and IR [13, 14]. Furthermore, fasting blood glucose and glucose disposal rate are
hypothesized to be among the most influential factors for impaired MF [15, 16].
Exercise intervention has been shown to enhance insulin sensitivity associated with a
reduction in whole body fasting respiratory quotient (RQ) in obese insulin-resistant individuals
[17] and improved MF in T2D [18]. A very recent study has shown that aerobic and resistance
exercise has similar lowering effects on fasting blood-glucose and improvements in insulin
sensitivity, yet combination of the two has an additive effect [19]. However, to our knowledge
there have been no studies examining the relationship between long-term resistance training
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intensity and fasting blood glucose in FH+ using traditional multi-set and fast-paced circuit
training.
The preference of exercise modality for possibly delaying or preventing the development of
T2D in this at-risk population has not been examined. Furthermore, it is unclear whether risk
factors such as fasting blood glucose can be altered in a young, apparently healthy FH+
population with different forms of resistance training. Since impaired MF is directly related to
fasting blood glucose [15], and has been observed in young, active FH+ population (Russell et
al., unpublished data), it is important to further examine whether or not specific exercise
programs are more helpful than others at reducing this risk factor.
Therefore, the present study compared the clinical benefits of traditional resistance training
focused solely on strength gains vs. fast-paced resistance circuit training designed to maintain
highly elevated heard rates in healthy young people with (FH+) and without (FH-) a family
history of T2D. Changes in estimated maximal strength in bench press, squat, and dead-lift were
used to assess effectiveness of training modality. Fasting blood glucose concentrations were
assessed before and three days after intervention in both groups. It was expected that strength
progression would be similar for both modes of training, and that circuit training would result in
more significant reductions in fasting blood glucose concentrations. Finally, it was expected that
FH- would have greater reductions in fasting blood glucose than FH+.
Methods


Subjects.
14 FH- and 9 FH+ subjects were recruited from the Baton Rouge area using local

advertisements and word of mouth to participate in a 7-week study examining the effects of
resistance training on fasting blood glucose. FH+ was categorized as being a 1st or 2nd degree
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relative of a person with T2D. The subject population consisted of fourteen healthy, active
controls with no family history (FH-) of diabetes, and nine healthy active FH+. Age, gender,
BMI, and activity were matched between FH+ and FH-. The purpose, potential risks and benefits
of participation in the study were fully explained to each participant before written consent was
obtained prior to testing. The study was approved by the Ethical Committee of Louisiana State
University (LSU office of IRB). All FH+ and FH- subjects had normal fasting blood-glucose
prior to testing using a hand-held finger-prick glucose meter. Additional inclusion criteria for
FH+ and FH- groups were no overt disease, physically active, blood-glucose concentrations
under ten mmol/L (180 mg/dL) an hour after glucose loading, BMI between 18.5-24.9 kg per m2,
and not taking prescription medication other than oral contraceptives. A physical activity
questionnaire was completed prior to participation in the study. Subject characteristics were
summarized in Table 3.1.


Research Design.
The study consisted of three main parts. 1) a pre-training test day including fasting and post-

exercise blood glucose followed by determination of calculated maximal strength on bench
press, squats, and dead-lift, 2) 7-weeks of resistance training using either traditional multi-set
resistance training or fast-paced single-set circuit training, and 3) a post-training test day
including fasting and post-exercise blood glucose and re-evaluation of calculated maximal
strength. Participants were instructed not to perform strenuous exercise, nor consume alcohol or
caffeine at least two days prior to either test day.


Blood-Glucose.
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Table 3.1 Subject characteristics: Age (years), Height (cm), Weight (kg), and Body Mass Index
(BMI). Mean ± SE.

Age (years)
Height (cm)
Weight (kg)
BMI

FH+
23.0 ± 1.1
170.5 ± 2.9
70.6 ± 3.2
24.3 ± .06

FH24.1 ± 2.0
173.8 ± 1.9
73.0 ± 3.2
24.2 ± .05
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P
NS
NS
NS
NS

After a ten-hour fast, blood glucose was measured using an AccuChek CompactPlus glucose
monitor (Indianapolis, IN), a precise and reliable means of assessing blood-glucose [20]. Bloodglucose measurements were taken after ten minutes of rest, and then each participant was given a
110 kcal breakfast snack bar containing 3g fat, 110mg sodium, 24g carbohydrate, and 2g protein.
Blood glucose was re-evaluated immediately after (time 0), and 10 minutes after (time 10) both
test day workouts. Participants were asked to record their diet the day prior to the first test day,
and repeat the same diet on the day preceding the post-training test day. Blood lactate was also
measured at the same time as glucose, using a lactate monitor (Lactate Pro, Quesnel, BC).


Exercise Training.
Two kinds of training modalities were utilized. Each modality included exercising five days

per week, with resistance training on Monday and Friday, core body work on Tuesday and
Thursday, and explosive interval training on Wednesday (Figure 3.1). Eight participants
performed 7 weeks of traditional, multi-set resistance training featuring two sets of resistance
exercise for each muscle group, the second set going to complete muscular fatigue of: squat,
bench-press, lateral pull down/seated row, shoulder press, push-up, bicep curl, tricept extension,
and dead-lift exercises. Training progression was continuously monitored and load adjusted for
all participants in both exercise groups to ensure that each participant increased the resistance
load with increasing strength, enabling all participants to continue to work out at 65-85% of
1RM for each workout. Sixteen participants performed 7-weeks of fast-paced circuit resistance
training featuring one set to complete muscular fatigue of the same exercises. One participant
from the circuit group was excluded for non-compliance. Both groups had similar ratios for
gender and family history. Both groups began training on the same day an hour apart, and
performed the same exercises. Each group was encouraged to reach muscular fatigue within 8-12
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repetitions at 65-85% of calculated 1-repetition maximum (1RM). If more repetitions were
required to achieve complete muscular fatigue, weight was increased on the subsequent workout.


Analyses.
Strength assessment was conducted via a modified Epley formula [21]:

Where r = repetitions, w = weight lifted. After a thorough warm-up, each person attempted one
set of bench press, squats, and dead-lift to complete muscular fatigue, then used the formula
above to estimate 1RM. Blood glucose and lactate concentrations were assessed via finger prick
as described above.

All statistics were calculated using SPSS 17 (Somers, NY). Subject characteristics were
analyzed using comparison of means. Variables such as fasting blood-glucose and lactate
differences between groups were calculated using a 1-way ANOVA. Pre to post-training group
changes in blood-glucose and lactate concentrations were analyzed using repeated measures
ANOVA, factoring family history. Pearson product moment correlations were used to determine
relationship between variables. All comparisons were considered significant at the alpha level p
≤ 0.05.
Results
Prior to training, there were no differences in blood glucose or calculated maximal strength
between FH+ and FH-. No differences in strength increases or fasting blood glucose
concentrations were noted between the two different training modes. Strength increased from pre
to post training similarly in both groups (Table 3.2), while fasting blood glucose concentrations
were significantly lower after training overall, with a strong trend towards FH- having the greater
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Figure 3.1 Illustration of workout schedule for each week in both exercise modalities.

44

Table 3.2 Training-induced changes in strength and fasting glucose. Values represent mean ± SE.
P = overall group changes from pre to post training.

Strength
% Strength
Fasting BG

FH+
1430 ± 70.3
56.8 ± 46.9
-3.6 ± 7.5

FH168.7 ± 128.2
42.4 ± 32.9
-4.8 ± 6.5
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P
0.0001
0.0001
0.015

decrease (p = 0.17) (Figure 3.2).There was also a correlation between percent strength gains and
decreased blood glucose concentrations from pre to post training (r = -0.515, p = 0.046) (Table
3.2). Fasting glucose: lactate ratio was not different from pre to post training. However, from pre
to post training, glucose: lactate ratio was higher immediately after exercise, and lower five and
ten minutes after exercise (Table 3.3).
Discussion
There were no differences between FH- and FH+ in pre-training strength, BMI, or blood
glucose or lactate before or after exercise. The hypothesis that both modes of training would
illicit the same strength gains was supported, however, the subjects also yielded the same fasting
glucose and lactate responses with time. Therefore, data were combined from both modes of
training to increase statistical power for glucose and lactate changes with training in FH+ and
FH-. Fasting blood-glucose dropped in FH- and FH+ alike with training. Furthermore, changes
in glucose: lactate ratios were no different between groups, but increased immediately after
exercise with training, and decreased at five and ten minutes post-exercise with training.


Strength
With both modes of strength training yielding the same strength gains over 7 weeks, the two

modes were combined for greater strength in statistical analysis for glucose and lactate. A highvolume load for strength training was utilized to increase potential exercise benefits, specifically
since previous research indicates that 8 weeks of low-intensity, low-volume resistance is not
sufficient to decrease metabolic risk factors in T2D [22]. Strength increased on average nearly
57% with training overall. Resistance training is associated with not only increased strength as
seen in this study, but also with increased muscle mass and improved whole-body glucose
disposal rate [23]. Furthermore, a recent study indicates that similar resistance-type circuit
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Figure 3.2.Fasting blood glucose concentrations before and after 7 week resistance training.
Mean ± SE
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Table 3.3 Changes from pre to post training in Glucose: Lactate ratio. Values are mean ± SE.

0 Glu Lac Ratio
5 Glu Lac Ratio
10 Glu Lac Ratio

Pre-Training Post-Training
13.5 ± 1.1
9.46 ± 0.8
27.1 ± 3.5
14.8 ± 1.1
32.2 ± 3.6
27.9 ± 3.8
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P
0.034
0.001
0.003

training can decrease metabolic risk factors in young overweight males [24]. The increased
strength seen in this study would indicate that the stimulus used for resistance training was
sufficient to elicit a physiologic adaptation. However, lean muscle mass was not evaluated in this
study.


Fasting Blood Glucose
Fasting blood glucose decreased with training (Figure 3.2). Though there was a trend of FH+

not decreasing as much as FH- (p = 0.17), no significant differences were noted in fasting blood
glucose with training. This lack of significance between groups may be due to a small sample
population, or insufficient length of training duration. However, it is also possible that since
fasting blood glucose in both groups was already well within normal range, it was less likely to
observe significant differences in reduced fasting glucose than if this population had higher pretraining values. The overall decline in blood glucose concentrations indicates tighter
glucoregulatory control with resistance training. This may be due to greater glucose uptake in
muscle as previously indicated [23]. However reduced hepatic glucose release cannot be ruled
out since we did not measure the glucose source specifically. Therefore it was not possible to
distinguish between appearance and removal rates, and thus have only described what is acutely
visible in the blood at specific time points. Nonetheless, whether a fasting decrease was from
reduced appearance or increased removal, a tighter blood glucose regulation exists with training
further supporting previous studies indicating that this type of training reduces insulin resistance
[24, 25], independent of body mass changes.


Blood Lactate
In the current study, there were no changes in fasting lactate, however sharp increases in

lactate in both groups were observed immediately after exercise with seven weeks of training.
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This acute post-exercise lactate increase was attenuated significantly after training, along with
increased estimated 1-RM, indicate a significantly greater absolute workload was achieved after
seven weeks of training without increasing the relative workload. With training, there were
reductions in glucose: lactate ratio immediately post-exercise, and at five and ten-minutes postexercise. Though blood lactate was higher immediately after exercise with training, there were
no differences in blood lactate at five and ten minutes after exercise from pre to post training.
This indicates a greater rate of lactate removal with training (Figure 3.3). This greater decrease in
blood lactate concentrations may be an indication of greater oxidative enzyme capacity with
training, as lactate is removed by either oxidative muscle fibers adjacent to lactate-producing
glycolytic fibers or by liver [26, 27].
Simoneau and Kelley [28] showed that an increased ratio of glycolytic to oxidative enzymes
contributes to insulin resistance in skeletal muscle of patients with type 2 diabetes. Granted, the
current study was not designed to monitor lactate removal, nor to determine if the greater
decrease within ten-minutes of passive recovery was due to less lactate appearance, greater rate
of removal, or a combination of both. Since a large amount of lactate comes from glycogenolysis
[29], it is reasonable to assume that exercise training does not affect production of post-exercise
lactate in passive recovery to a great extent. Therefore, it is likely that lactate removal is
occurring at a faster rate after training. When considering that exercise up-regulates
mitochondrial biogenesis transcription factors like PGC-1α [30], and the various ways in which
lactate can be removed, including by oxidative muscle fibers [27], it is plausible to expect that
resistance training in the current study elicited an up-regulation of PGC-1α leading to increased
oxidative muscle fibers and higher mitochondrial content, leading to decreases in both fasting
blood glucose and 10 minute post-exercise blood lactate concentrations.
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Figure 3.3 Changes in blood lactate concentrations at 0 and 10 minutes after acute exercise,
before (Pre) and after (post) resistance training. Mean ± SE.
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Glucose: Lactate Ratio
As expected, there was no change in glucose: lactate ratio at rest with training. However,

with elevated lactate immediately post-exercise, combined with reductions in glucose: lactate
ratio after exercise with training indicate a greater lactate production with the greater absolute
workload and faster lactate removal with passive recovery. Though post-exercise blood glucose
concentrations were 104.4 ± 3.5 mg/dl (mean ± SE) after training, the glucose: lactate ratio was
significantly reduced at 0, 5 and 10 minutes post exercise with training, with no differences
between FH+ and FH-. Since the workout itself started with the largest muscle groups and
maintained a constant intensity for the entire10 minutes to completion, then ending with deadlifts, it is reasonable to believe that the blood lactate concentrations increased early and remained
high throughout the workout until a possible peak with dead-lift at the end, allowing lactate
measurements at time 0 to represent lactate at their highest concentrations. This was evidenced
by the reduction of lactate, and the glucose: lactate ratio at all time points. It is important to note
that the ten-minute recovery was passive. It is possible that both glucose and lactate may have
dropped more in this recovery period had it been active. However, in an effort to normalize
recovery somewhat between people with different muscle mass, passive recovery was chosen. It
is interesting to note that even with passive recovery, with training, this ratio at five and tenminutes post exercise was well below fasting levels. This may indicate that the recovering
muscles and liver, etc may be using a greater ratio of blood glucose to lactate for recovery with
training, especially since absolute lactate production post-exercise with training increased.


Conclusions
High-intensity resistance circuit training and traditional multi-set resistance training are

equally effective in increasing strength in moderately active young adults. Furthermore, fasting
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blood glucose is significantly reduced with seven weeks of resistance training, with a trend of
less reductions in FH+ than FH- (p = 0.17) similar to metformin use in obese adolescents [31].
Further research is needed to determine if longer duration training increases this significance,
and also to determine if resistance training can affect risk factors for the development of T2D in
this young FH+ population other than fasting blood glucose, for example, blood lipid profiles.
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CHAPTER 4: LIPOTOXICITY AND EARLY INSULIN RESISTANCE: EFFECTS
OF EXERCISE TRAINING ON LIPOTOXICITY MEASURES IN 1ST AND 2ND DEGREE
OFFSPRING OF DIABETICS
Introduction
Type-2 diabetes (T2D) is a pandemic disease [1] characterized by insulin resistance (IR),
which develops one to two decades before the onset of type-2 diabetes (T2D), [2, 3] and is the
best predictor for future development of this disease [3, 4]. Since IR is related to several comorbidities like elevated lipid levels, loss of metabolic flexibility (MF) and impaired
glucoregulatory function, much attention has been given to studying these co-morbidities. IR
subjects not only display elevated fasting β-oxidation, but also impaired MF, which is
characterized by impaired ability to switch to carbohydrate as substrate from the fasted-to-fed
transition (Russell, et al., unpublished data, [5]). Several factors are likely to contribute to the
development of this condition, including decreased hexokinase activity and peroxisome
proliferator-activated receptor gamma coactivator 1α 1 (PGC1) expression, which are both seen
in T2D [6]. One prominent theory suggests that muscle insulin resistance arises from impaired
mitochondrial uptake and oxidation of fatty acids [7]. In this process, disturbances of free-fatty
acid/nonesterified fatty acid (FFA/NEFA) metabolism, elevated basal rate of lipolysis, and
impaired suppression of plasma NEFA concentration by insulin, are also associated with IR and
reduced MF [8-10]. Although there is a strong indication that these factors are related to
mitochondrial dysfunction and impaired MF, with so many co-morbidities and additional
confounding factors (like obesity and impaired glucoregulatory function) often present in T2D
patients, it is difficult to distinguish which factor may be the initial trigger for developing IR.
Interestingly, IR individuals with a positive family history of diabetes (FH+) may be an ideal
group in which to study the initial development of diabetes and its earliest co-morbidities for
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several reasons. These individuals have been shown to be at approximately 40% higher risk for
developing T2D than those with no family history (FH-) [2, 11], and have impaired hexokinase
II activity and PCG1α 1 expression similar to T2D [12] [6] which may lead to decreased
expression of Nuclear respiratory factor-1 (NRF-1), which is a key transcription factor involved
in regulating mitochondrial DNA transcription [6]. In addition, previously unpublished work
from our lab indicate they also exhibit impaired MF similar to T2D, yet have similar
glucoregulatory function as those with no family history. The benefit of studying IR in this
population is that these individuals often have not yet developed many of the confounding
factors that may contribute to the development of T2D, like glucotoxicity or obesity, yet they
display a 50% reduction in the rate of insulin-stimulated whole-body glucose metabolism due to
decreased muscle glycogen syntheses rates [11]. This suggests that the pathogenesis of T2D in
the FH+ population can be examined at its earliest time points [7]. To date, much of the research
on FH+ has been in IR FH+ only, making it difficult to isolate what pathologic connection is
shared between FH+ and T2D leading to the development of IR, which makes FH+ more likely
to develop diabetes [13, 14]. However, previously unpublished data from our lab shows that FH+
population not only has impaired MF similar to T2D, but also may have a less favorable
glucoregulatory improvement in response to resistance training. However, it is not clear what
metabolic factors may be involved in the impaired MF of FH+, though recent studies would
suggest problems with lipid metabolism being a likely culprit [8-10].
Therefore, the purpose of the current study was to determine whether differences in markers
of lipotoxicity and glucoregulatory function exist between young, active FH+ and FHpopulations, and to compare possible changes in response to resistance training. Data from the
present study could potentially aid in development of effective screening tools and interventions
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to prevent T2D progression in the FH+ population. It was hypothesized that markers of
lipotoxicity and cardiovascular disease would be elevated in FH+ as compared with FH- prior to
training, and that these markers will decrease less in FH+ than FH- with resistance training.
Methods


Subjects.
Twenty-three subjects were recruited from the Louisiana State University student population

to participate in 6.5 weeks of resistance training, and one morning of fasting blood testing before
and after training. FH+ was categorized as being a 1st or 2nd degree relative of a person with
T2D. The subject population consisted of 10 healthy, active controls with no family history (FH) of diabetes, and 13 FH+ subjects. Age, gender, BMI, and activity were matched between both
groups. The purpose, potential risks and benefits of participation in the study were fully
explained to each participant before written consent was obtained prior to testing. The study was
approved by the Ethical Committee of Louisiana State University (LSU office of IRB). All FH+
and FH- subjects had normal fasting blood-glucose prior to testing using a hand-held finger-prick
glucose meter (AccuChek CompactPlus, Indianapolis, IN). Additional inclusion criteria for FH+
and FH- groups were no overt disease, capable of physical activity, blood-glucose concentrations
under 10 mmol/L (180 mg/dL) an hour after glucose loading, and not taking prescription
medication other than oral contraceptives. A physical activity questionnaire was completed prior
to participation in the study. Subject characteristics are summarized in Table 4.1.


Research Design.
Subjects were tested prior to, and 3 days after training. The testing consisted of two

components: 1) assessment of blood glucose concentration responses to an oral glucose load, and
2) fasting blood samples drawn and centrifuged to separate and freeze the plasma until further
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Table 4.1 Pre-training values for FH- and FH+. Age (years), weight (kg), BMI, fasting blood
glucose (BG, mg/dl), Tryglyceride (mg/dl), NEFA (mM/L), Insulin (mmol/L), Homeostatic
model assessment (HOMA) and acylcarnitine (C18-2). Values are mean ± standard error.

Age
Weight
BMI
Fasting BG
OGTT AUC
Triglyceride
NEFA
Insulin
HOMA
C18-2

FH+
23.0 ± 1.1
76.7 ± 5.3
26.7 ± 1.7
86.2 ± 2.6
125.9 ± 5.4
107.4 ± 7.8
384.5 ± 64.9
10.8 ± 3.2
2.3 ± 0.7
0.03 ± 0.0

FH24.1 ± 2.0
64.8 ± 4.9
23.5 ± 1.2
82.7 ± 3.2
125.7 ± 5.3
128.7 ± 12.0
441.1 ± 37.0
7.5 ± 2.4
1.5 ± 0.4
0.04 ± 0.0

P
NS
NS
NS
NS
NS
NS
NS
NS
NS
0.04
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analysis. The training component of the study consisted of 6 ½ weeks of fast-paced circuittype resistance training as used in previous studies (Russell et al., unpublished data). This
method was shown to be as effective as traditional multiple set resistance training for increasing
strength and reducing fasting blood glucose concentrations (Russell et al., unpublished data).


Glucoregulatory Assessment.
While still fasting, each participant consumed a solution of 50g glucose dissolved in 10oz of

water. Each glucose beverage was consumed within two minutes while resting. Finger prick
capillary glucose was determined via a glucometer (AccuChek CompactPlus, Indianapolis, IN), a
precise and reliable means of assessing blood-glucose [15]. Finger prick and glucose
measurements were determined every twenty minutes for 1-hour to determine blood-glucose
responses to the oral glucose load, similar to studies examining postprandial hyperglycemia, a
well-recognized risk-factor of T2D [16, 17]. Previous data from our lab indicates that a 60
minute modified oral glucose tolerance test (OGTT) is sensitive enough to differentiate
glucoregulatory function between FH+ and T2D (Russell et al., unpublished data). Furthermore,
a 60-minute OGTT has been shown to better determine glucoregulatory impairment in pre IGT
patients [18].


Fasting Blood Samples.
Fasting blood samples were drawn using both EDTA and heparinized vaccutainers by a

licensed phlebotomist prior to administration of the oral glucose beverage, and were centrifuged
at 4 degrees C for ten minutes at 3500 RPM. The plasma was pipetted and quickly frozen at -80
degrees C and stored until analysis. Triglycerides (Teco Diagnostics, Anaheim, CA) and nonesterified fatty acids (Roche Applied Science, Indianapolis, IN) were determined
spectrophotometrically according to kit manufacturer’s instructions. Insulin was assessed using
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an enzyme immunoassay kit from ALPCO Diagnostics (Salem, NH) according to manufacturer’s
instructions.
Acylcarnitine profiles were measured in collaboration with Dr. Indu Kheterpal, Director of
the Proteomics and Metabolomics Core Facility at Pennington Biomedical Research Center.
For mass spectrometric analysis of acylcarnitines, 50 µL of blood plasma/serum was
supplemented with a mixture of deuterium labeled acylcarnitines (Cambridge Isotope Labs.) as
internal standards. Samples were de-proteinized with acetonitrile, and the supernatant was dried
under nitrogen at 50 ˚C. The residues were incubated with 3M Butanol-acetylchloride at 50 ˚C
for 15 min to form butyl ester derivatives of the acylcarnitines. The reagent was evaporated
under nitrogen and samples were resuspended in 150 µL of acetonitrile/water/formic acid
(80/20/0.1). An electrospray ionization (ESI) tandem quadruple mass spectrometer (XEVO
TQMS, Waters, Corp., Milford, MA) equipped with an Acquity ultra performance liquid
chromatography system (Waters Corp., Milford, MA) was used for acylcarnitine measurement.
Samples were directly injected into the ESI source of the MS and acylcarnitine profiles were
generated using precursor ion scan (m/z 85) function of the MS. Ratio of each acylcarnitine to
its assigned internal standard was used to determine concentration of each analyte.


Strength Assessment and Training.
Strength assessment was done via a modified Epley formula [19]:

Where r = repetitions, w = weight lifted. After a throughout warm-up, each person attempted
one set of bench press, squats, and deal-lift to complete muscular fatigue, then used the formula
above to estimate 1RM. Participants exercised five days per week, with resistance training on
Monday and Friday, core body work on Tuesday and Thursday, and explosive interval training
61

on Wednesday (Figure 4.1). Eight participants performed 6.5-weeks of fast-paced circuit-style
resistance training consisting of one set to complete muscular fatigue of: squats, bench-press,
lateral pull-down/seated row, shoulder press, push-ups, bicep curls, tricept extension, and deadlifts. Each participant was encouraged to reach muscular fatigue within 8-12 repetitions at 6585% of calculated one repetition max (1RM). If more repetitions were required to achieve
complete muscular fatigue, weight was increased on the subsequent workout.


Statistical Analyses.
All statistics were calculated using SAS 9.2 (Somers, NY). Subject characteristics were

analyzed using comparison of means. Principal components analysis was used as a means of
data-reduction and clustering relevant acylcarnitines and to correlate levels of specific AcylCN
species with metabolic parameters. Pre-training variables such as blood-glucose concentration
after glucose loading, strength, BMI, or lipotoxicity markers between untrained groups, were
calculated using one-way ANOVA. Changes with training between groups were analyzed using
repeated measures ANOVAs.
Results


Pre-Training.
No pre-training differences existed between FH- and FH+ in estimated strength,

glucoregulatory function as per 60-minute modified OGTT, fasting blood-glucose, body weight,
TG, NEFA, insulin or Homeostatic Model Assessment (HOMA) (Table 4.1). Most acylcarnitines
were not different between groups prior to training, except for C18-2 p = 0.042 which was lower
in FH+ (p = 0.04). FH+ display lower levels of the long-chain acylcarnitine, C18-2 as compared
with FH-.
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Figure 4.1 Illustration of workout schedule for each week in both exercise modalities.
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Training.
Training progression, measured as estimated strength increases in bench press, squat and

dead lift, were the same in both groups. There were overall changes with training in body weight,
BMI and strength (p < 0.05). A trend in greater weight loss was noted in FH+ (p = 0.065), with
BMI being significantly lower in FH+ with training.
There was also a significant decrease in fasting plasma NEFA with training. However, there
was no significant difference in NEFA change between groups with training (Figure 4.2).
Principal components revealed several acylcarnitines are primarily responsible for the variation
in metabolic data (Table 4.2), with two short-chain acylcarnitines, C3:1 and C4-OH, changing
differently with training between FH- and FH+. When groups were separated according to
weight loss (WL+) or no weight loss (WL-), there was a significant increase in plasma insulin
with the WL+ group over WL- with training.
Discussion
Neither of the hypotheses was supported as there were no differences between FH- and FH+
pre-training strength, BMI, or in markers measured in plasma before or after exercise. Strength
increased from pre to post training similarly. However, changes in NEFA and insulin were noted
in non-weight loss weight loss subjects vs. (Figure 4.3). Negative correlations were observed
between weight loss and: TG, NEFA, insulin and HOMA, and strength, and positive correlations
were found between weight loss and blood glucose AUC.


Glucoregulatory Function.
Although changes in blood glucose concentrations for fasting, 60-minutes post glucose

beverage consumption, or with area-under-the-curve (AUC) for the 60-minutes of observation
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Figure 4.2 Mean ± SE. Changes with training (NEFA –Top, and strength- Bottom) in FH- and
FH+. p = 0.05
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Table 4.2 Rotated factor pattern from principal components analysis of acylcarnitines showing
important correlations with metabolic profile. Significant correlations are bold.

CN
C3
C4
C5
C6-OH
C8-1
C10-3
C10-2
C18/C12:1DC
C20:4
C20/C14:1DC
C14-DC
C22/C16:1DC
C18-DC

4
0.62
0.68
0.72
0.68
0.56
-0.08
0.11
0.26

Component
5
-0.02
-0.04
-0.08
0.9
-0.28
-0.02
0.06
0.12

6
-0.03
-0.04
0.05
0.11
0.33
0.84
0.8
0.59

0.18
0.64

0.76
0.01

0.08
0.09

0.18
0.06

0.83
0.52

-0.02
0.15

-0.34
-0.17

0.77
0.57

-0.1
0.21
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Figure 4.3 Mean ± SE. Plasma NEFA (mM/L) and insulin (mmol/L) changes before (Pre) and
after (Post) resistance training with and without training-induced weight loss. p = 0.05
*Significant change from pre to post training.
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function increased (as per decreased glucose AUC) from pre to post training with weight loss.
However, when examining the group that lost weight by itself using a paired T-test, there was a
significant improvement in blood glucose AUC with training. However, no significant
differences in glucoregulatory function existed between FH- and FH+ before or after training.
This would imply that body weight and caloric balance are more important for overall
glucoregulatory function than a family history of T2D.


Non-Esterified Fatty Acid.
NEFA is produced from lipolysis of stored triglycerides in adipocytes which delivers NEFAs

to the plasma, from where they are taken up by the metabolizing tissues, mainly skeletal muscle,
heart and liver [20]. In the current study, there was a significant reduction in NEFA
concentrations overall from pre to post training (p = 0.008) with no differences between FH- and
FH+. This may indicate a reduced reliance on fasting FA metabolism with resistance training,
and thus diminished lipolysis, an increase in insulin to enhance liponeogenesis and reduce NEFA
production, or enhanced NEFA uptake by muscle or liver. There were also no differences in pretraining NEFA concentrations between FH- and FH+. However, a correlation exists between
NEFA and blood glucose AUC, indicating that NEFA may affect glucoregulatory function, and
the early development of IR. Since insulin is known to stimulate liponeogenesis [20], it should
also reduce overall NEFA appearance in plasma. However, no correlations were noted between
changes in insulin and NEFA concentrations in either group, though insulin was increased posttraining in the weight loss group. This increase in insulin may help explain the overall decrease
in NEFA production with training, however the plasma NEFA decrease was universal across all
groups where increased insulin was limited to weight loss only, thereby implying that resistance
training may lead to more efficient FA metabolism (removal) in the fasting state.
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Insulin and HOMA.
There were no differences in insulin concentrations or HOMA between FH- and FH+ prior to

training. Likewise, there were no significant changes in the overall group with training for either
insulin concentrations or HOMA, but when FH+ group was analyzed separately, there were
significant increases in insulin and HOMA with training. However, these increases were
accounted for when factoring in weight loss. Contrary to initial speculation, losing weight is
attributed to increased insulin and HOMA in the current study. This is likely due to the lack of
dietary control, meaning that all weight loss came from increased energy costs associated with
exercise; and since the post-testing did not occur until 3.5 days after the last exercise bout, the
energy balance had begun to shift back towards weight gain. Being in a positive energy balance
causes an increase in insulin and HOMA to initiate liponeogenesis and subsequent weight gain.
This change was independent of decreased glucoregulatory function however, which might be
attributed to the increased lean muscle mass often associated with resistance training [21], but
not likely to the acute affects of exercise since over three days had passed between exercise and
testing.


Triglyceride.
In order to examine the chronic, rather than acute effects of resistance training, blood

samples were collected from the participants three days after the final exercise session.
Triglycerides did not differ between groups either before or with training. This appears to
contradict aerobic studies showing an improvement in these parameters [22], however, previous
resistance training studies have yielded variable results [21, 22]. These differences are likely due
to large variations in participant populations, training volume, study duration, modality, and
intensity. For the current study, high-intensity circuit training in a young, healthy population did
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not elicit any changes overall in plasma TG or insulin. It should be noted that plasma NEFA
concentrations significantly decreased post-training while TG did not, indicating that fatty acid
transport into muscle cells is up-regulated as a result of resistance training while lypolysis may
not be up-regulated.


Acylcarnitine.
Acylcarnitines are metabolic byproducts of incomplete substrate degradation formed from

their respective acyl-CoA intermediates by a family of carnitine acyltransferases that reside
principally within mitochondria. Most even chain species reflect incomplete fatty acid oxidation,
and odd chain species from amino acid catabolism, whereas acetylcarnitine is derived from
acetyl-CoA, the universal degradation product of all metabolic substrates [5, 23, 24].
In the current study, there was only one acylcarnitine that was different between groups
before training, C18-2, and seven after training. However, very little is known about C18-2 and
any associations with aberrant lipid metabolism. However, virtually no differences in
acylcarnitine levels were displayed between groups either before or after training. This would
imply that there is not yet a breakdown in lipid metabolism or acylcarnitine transport into the
mitochondrial matrix in healthy active FH+ as compared with FH-.
Interestingly, C3-1 and C4-OH, which have been shown to be elevated in T2D [25],
decreased more in FH+ than FH- with training. C3-1 is derived from amino acid catabolism, and
C4-OH from incomplete fatty acid oxidation. Elevated C4-OH in particular has been wellcharacterized in the literature as being associated with Medium/Short-chain hydroxyacyl-CoA
dehydrogenase (M/SCHAD) deficiency, a fatty acid oxidation disorder characterized by
increased metabolic demands on fat oxidation [26]. Though fat oxidation was not specifically
assessed, the decreased C3-1 and C4-OH with training moves both groups further from levels
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seen in T2D. With normal clinical values ranging between 0 and 0.4 [27], any reduction can be
seen as improvement since there is no lower limit, and is evidence of properly-functioning
SCHAD enzymes used for fat oxidation. Thus, in both FH- and FH+, similar quantities of
NEFAs are readily activated into AcylCN that can either pass into the mitochondria via carnitine
AcylCN translocase or can exit the cell for other disposal. Inside the cell, the AcylCN is deesterified back to acyl-CoA and enters the β-oxidation spiral [25]. However, given the decrease
in circulating NEFA with training, it would be expected to see more of a reduction in
acylcarnitines associated with the NEFA decrease.
Given the data indicating impaired metabolic flexibility in FH+, future research is needed to
determine if acylcarnitine levels decrease with inhibited NEFA production via hyper-insulinemic
clamp metabolic flexibility studies. With the added insulin suppressing NEFA production, there
should be decreased acylcarnitine production displayed in the plasma in metabolically flexible
individuals as compared with T2D or FH+.


Limitations.
As previously mentioned, the post-exercise intervention blood samples were collected three

days after the completion of the study which impacted plasma TG and insulin levels. In addition,
due to limited resources, diet was not controlled or measured for this study, however all fasting
was done after an overnight fast, and all participants were instructed to maintain a similar diet
throughout training, and prior to both test days.


Conclusion.
Though there are differences between groups with and without a family history of diabetes

(Russell et al., unpublished data) [2, 11, 12], this study does not reveal any such differences in
glucoregulatory function, or markers of lipotoxicity. Resistance training did not affect FH+
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differently than FH-, however there were differences in these markers when groups were recategorized by weight loss. We were unable to isolate specific factors likely to contribute to the
development of IR or T2D within the confines of the current study. However, further research,
such as lipid tracers and MRI studies are needed to determine factors leading to more aberrant
metabolic function in order to better understand what factors lead to the development of IR and
T2D.
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CHAPTER 5: GENERAL DISCUSSION
Type-2 diabetes (T2D) is a pandemic disease [1] characterized by insulin resistance (IR),
which develops one to two decades before the onset of type-2 diabetes (T2D), [2, 3] and is the
best predictor for future development of this disease [3, 4]. Since IR is related to several comorbidities like elevated lipid levels, loss of metabolic flexibility (MF) and impaired
glucoregulatory function, much attention has been given to studying these co-morbidities. IR
subjects not only display elevated fasting β-oxidation, but also impaired MF, which is
characterized by impaired ability to switch to carbohydrate as substrate from the fasted-to-fed
transition [5], elevated mitochondrial reactive oxygen species (ROS) production [6, 7], and
markers of lipotoxicity [8, 9] which in turn lead to even more enhanced ROS production [6, 10].
In addition, disturbances of free-fatty acid/nonesterified fatty acid (FFA/NEFA) metabolism,
elevated basal rate of lipolysis, and impaired suppression of plasma NEFA concentration by
insulin, are also associated with IR and reduced MF [11-13].
Interestingly, IR individuals with a positive family history of diabetes (FH+) may be an ideal
group in which to study the initial development of diabetes and its earliest co-morbidities for
several reasons. These individuals have been shown to be at approximately 40% higher risk for
developing T2D than those with no family history (FH-) [2, 14], and have impaired hexokinase
II activity and PCG1 expression similar to T2D [15, 16] which may lead to decreased expression
of NRF-1 [16]. This suggests that the pathogenesis of T2D in the FH+ population can be
examined at its earliest time points [9]. To date, much of the research on FH+ has been in IR
FH+ only, making it difficult to isolate the pathologic connection is shared between FH+ and
T2D leading to the development of IR, that makes FH+ more likely to develop diabetes [17, 18].
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Therefore, the purpose of the current document was to categorize aberrant metabolic
characteristics in healthy, active FH+ independent of IR to better understand which factors in this
population are differ from age and activity matched FH- which may preceed the development of
IR.
Key Results
In order to better understand the development of IR and T2D, it is important to isolate the
earliest mechanisms that may lead to IR. Therefore, healthy, active FH+ were used as a model of
earliest IR. However, many studies have examined FH+ with IR, and compared them to FHwithout IR. For contextual purposes, it is important not only to understand how FH+ are similar
to T2D, but also how they may differ from matched FH- as well. Therefore, Chapter 2,
experiment 1 examined metabolic characteristics, including metabolic flexibility (MF), fasting
metabolism and substrate selection with a metabolic stimulus in T2D, FH- and FH+. Passive
stretching led to a short-lived increased CHO use in T2D, FH+, and FH- populations with
significant reductions in blood-glucose, especially in T2D. Fat use with stretching remained
similar throughout each group in contrast to previously reported fat oxidation differences in T2D
[15, 19, 20]. An oral dose of glucose led to increased CHO use in all groups, with significantly
higher CHO use in FH- than either FH+ or T2D. Furthermore, change in RER with oral glucose
(MF) was far greater in FH- than either FH+ or T2D, which exhibit equally reduced MF as
compared to FH-. Since this experiment indicated a reduction of MF in FH+, and since fasting
blood glucose is a major contributor to impaired MF [21], FH+ either with no IR, or low-level IR
may be an ideal group to study mechanisms that could potentially lead to the development of IR.
Chapter 3, experiment 2 examined the relationship between resistance training and fasting
blood glucose in FH+ and matched FH-. It was noted that fasting blood glucose was significantly
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reduced with seven weeks of resistance training, with a trend of less reductions in FH+ than FH(p = 0.17). Given the duration of the study, it is likely that by increasing the training duration
from seven weeks to several months, the differences in fasting blood glucose decreases would
have been significant if the observed pattern remained constant. Furthermore, if this kind of
exercise is maintained over several years, results may show significant clinical differences
between the two groups. Although the pre-training blood glucose values were not above normal,
this may be an indication that FH+ has slightly diminished glucoregulatory capacity than FH-.
However, impaired glucoregulatory function is the result of a breakdown in one or more of the
various metabolic processes. Therefore, to better understand why FH+ seems to be metabolically
different than FH-, Chapter 4, experiment 3 examined glucoregulatory function, and fasting
markers of lipotoxicity before and after resistance training. Though there are differences between
groups with and without a family history of diabetes (Russell et al., unpublished data) [2, 14, 15],
this study did not reveal any such differences in glucoregulatory function, or markers of
lipotoxicity. Resistance training did not affect FH+ differently than FH-, however there were
differences in these markers when groups were re-categorized by weight loss. It was not possible
to illustrate specific factors likely to contribute to the development of IR or T2D within the
confines of the current study.
Limitations
The biggest limiting factors for the above studies were, 1) limited subject pool, and more
importantly, 2) lack of resources for scientific analysis. Finger-prick glucose monitoring, while
simple, fast, inexpensive, and reproducible [22], is not the most accurate means of testing bloodglucose. Furthermore, the oral glucose tolerance tests (OGTT) performed in these experiments
were conducted for one-hour rather than two. The reason for this is that decreases in blood-
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glucose concentrations were noted within 60 minutes after consuming the glucose beverage, and
had already dropped below 180 mg/dl, the standard for hyperglycemia. Furthermore, plasma
acylcarnitines are a snapshot of lipid and amino acid breakdown, but do not give a complete
picture. Therefore, they were examined in the context of circulating triglycerides, NEFA, and
insulin as well. However, without muscle biopsies, it is not clear if the levels of metabolites
remained unchanged with training because: 1) training did not affect lipid metabolism, 2) either
increased or decreased production was matched by decreased/increased removal/metabolism.
Future Research
The above experiments have mainly focused on simple and inexpensive methods of testing.
However, it is likely that with more advanced technology, aberrant metabolic pathways leading
to IR may be easier to establish. For example, passive stretching yielded increased CHO use as
determined by indirect calorimetry, and decreases in blood glucose concentrations. However, the
increased CHO use stopped with the cessation of passive stretching. Therefore additional testing
using various isocaloric exercise intensities may alter recovery kinetics in T2D so that CHO is
used for a longer time period post-exercise, further enhancing glucoregulatory control. Though
chapter 2 illustrated impaired MF in FH-, further investigation on substrate switching from rest
to exercise and recovery using could aid in our understanding of MF since the current trend of
MF testing is under resting conditions in which demand for fat metabolism at rest is very low. In
addition, post-exercise MRI may indicate what and how substrates are used after a bout of
exercise in different diseased populations as compared to FH+.
Also, differences between plasma and muscle acylcarnitines, in conjunction with carnitine
quantification, a fatty acid transporter, may help elucidate possible breakdowns in lipid
metabolism, especially taken in the context of lipid availability, i.e., triglycerides, NEFA, and
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intramyocellular triglycerides (IMCT). Additionally, further research, such as lipid tracers and
MRI studies are needed to determine factors leading to more aberrant metabolic function in order
to better understand what factors lead to the development of IR and T2D. Taken together, lipid
tracers should be used to label specific dietary fats so they can be traced via MRI as:
triglycerides  adipose tissue  NEFA  IMCT  acylcarnitines. Such a study incorporating
T2D, healthy active FH+ and matched FH- can illuminate the current understanding of how
breakdown in lipid metabolism occurs and will aid in uncovering how increased lipid
metabolism contributes to IR.
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Introduction:


Overview of Social and Economic implications from Diabetes
Diabetes is a major cause of morbidity and mortality in the United States [1] resulting in

substantial human and economic costs [1], [2]. The U.S. Census indicates that the incidence of
diagnosed diabetes in the United States has increased rapidly, and that the major predictive cause
of diabetes is obesity [3]. According to the CDC, approximately 20.8 million people were
suffering with diabetes in 2005, and of those, 90-95% had non-insulin dependent diabetes
mellitus (type II diabetes, or DMII) (http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf). The
National Health Interview Survey indicates that 85% of all Americans with diabetes require
either oral medication or insulin infusion to maintain optimal health [4].
Heart disease and stroke account for 65% of deaths in people with diabetes. This is
approximately four times higher in adults with diabetes. Other secondary health problems
associated with diabetes are hypertension, blindness, kidney disease, nervous system damage,
amputations, dental disease and other metabolic problems
(http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf), leading to increased morbidity and
health care cost.
The cost of health care in the United States is an estimated $1.3 trillion (National Institute of
Health Sciences). The cost of treating a person with chronic disease or disability is substantially
higher than a healthy person the same age. For instance, in 2004 a 50-year old man recently
diagnosed with diabetes has an annual health care cost of $4174 higher than a 50-year old
without diabetes [5]. Each year, the cost of treating a person with diabetes increases by as much
as $140 over the cost of somebody who is aging without diabetes or its complications [5]. That is
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a total increased health care cost of up to $868,192,000,000.00 each year for the 20.8 million
diabetic people that over and above their expected treatment cost if they did not have diabetes.
That number increases by $55-$140 each year, for each of the 20.8 million people. This is an
increase of between $114 million and $400 million in health care costs each year just with the
incidence of diabetes.
Government spending on health care (Medicare/Medicaid) makes up most of the cost of
people diagnosed with DMII (National Institute of Health Sciences). Even if only half of all
people with DMII are on government insurance, there is still as much as a $1,456,000,000.00
increase in health care spending each year being by the Federal Government on a condition that
is often preventable, and highly treatable with proper diet and exercise [6]. Reducing the
prevalence of DMII would not only increase the quality of life for millions of people, but also
help the economy by reducing government spending on healthcare. As previously stated,
exercise and diet are effective tools in prevention and treatment of DMII, but the exact
mechanism through which they work is uncertain.


Purpose
That being said, the purpose of the following review is to provide an in-depth review of the

influence of exercise training on oxidative stress and how it affects insulin sensitivity in resting
metabolism in persons with DMII.


Oxidative stress: a potential mechanism
A current theory about the progression of DMII is increased oxidative stress [7]. Both pro-

oxidants (reactive oxygen species (ROS), e.g. hydrogen peroxide (H2O2), superoxide (OH-), and
peroxynitrite (ONOO-)] and antioxidants [e.g. superoxide dismutase (SOD), catalase (CAT),
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glutathione (GSH), and glutathione peroxidase (GPx)] exist naturally in the body. When the
antioxidant system cannot change ROS to H2O2 and then to water as quickly as ROS is produced,
the shift in pro and antioxidant balance is termed oxidative stress [8]. When this shift becomes
large enough to cause damage to either protein or fat, it is termed oxidative damage [8]. In
diabetics and pre-diabetics, there are higher levels of oxidative stress and oxidative damage after
an overnight fast, indicating that oxidative stress may be a possible cause of insulin insensitivity
leading to DMII [9].
At rest, a healthy person’s metabolism uses mostly fat as an energy source. However, fat,
glycogen, and creatine phosphate are used at all times in various ratios. In order to maintain a
healthy blood glucose level, insulin is needed to transport glucose into the cell for metabolism.
With DMII, not only are tissues less sensitive to insulin making glucose transport more difficult,
but there is also an increase in both lipid peroxidation and oxidation of proteins, which may lead
to increased production of pro-oxidants [9]. Ingestion of a high fat meal increases oxidative
stress in diabetics, and leads to further insulin insensitivity (Anderson, A.J., 2009 (ahead of
print)). With the link between resting metabolism and oxidative stress and the likelihood that
oxidative stress leads to insulin insensitivity, it is important to be able to detect and quantify
metabolism and pro and antioxidants in vivo.


Measurement tools
Oxidative stress measurements can be done on any one of several mediums (muscle, fat,

blood, or plasma). Traditionally when metabolism is in question, we see pro and antioxidants
measured in muscle since muscle controls the majority of one’s metabolism. Muscle biopsies are
a standard technique used to measure muscle antioxidants. A typical muscle biopsy sample and
handling procedure has been outlined by [9]. A muscle sample is taken by percutaneous needle
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biopsy from the muscle being examined, using local anesthetic to numb skin and subcutaneous
fascia. Muscle specimens (50–100 mg) are then frozen immediately in liquid N2 and stored at –
70°C. When all samples are taken from all participants, the frozen muscle is powdered under
liquid N2 and aliquots transferred to tubes containing various buffers for the analysis of the
different antioxidant markers. Commercially made kits for assays of pro and antioxidants, and
markers of oxidative damage are available from Millipore, Cayman Chemical, SABiosciences,
and BDBiosiences to name a few.
Adipose tissue also has metabolic properties of its own, and can be used for measuring
oxidative stress in adipose tissue. Samples are taken using similar techniques used for muscle
biopsies. However the metabolic activity of adipose tissue is very low compared to muscle, and
studies in this field are relatively new.
Blood and plasma are also used to determine oxidative stress and damage, especially when
cardiovascular disease is a concern. These techniques are much less invasive, and require a
simple blood draw and freezing of the blood sample until analysis. Commercial enzyme-linked
immunosorbent assay (ELISA) kits are readily available for multiple measures of oxidative stress
and oxidative damage in blood, and range in price from $250 to over $600. Blood assays will be
the focus of this dissertation as they are less invasive and less expensive.
Metabolic rate can be readily measured through two widely used non-invasive techniques,
direct and indirect calorimetry. Direct calorimetry requires a special room with extremely
sensitive equipment used to determine minute changes in temperature from oxygen being utilized
by the person in the room. It is very expensive and not many labs have this capability. The
simplest and cheapest way is to measure metabolism is through indirect-calorimetry. Indirect
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calorimetry measures the gas expelled from a person at rest to determine the change in
composition from expelled air and ambient (inspired) air. By examining differences between
ambient oxygen, and expelled oxygen, we can calculate oxygen consumption (VO2), carbon
dioxide production (VCO2), respiratory quotient (RQ) or respiratory exchange ratio (RER), and
resting energy expenditure (REE). For example, to calculate REE, we can use:

 

 kcal  
REE  n
 VO2 where n is the estimated amount of kcal used to burn one liter of oxygen.
 L O2 
Actual values of n are listed in the table below:
Caloric Equivalents for Oxygen and Foodstuff Contributions for various Nonprotein Respiratory
Exchange Ratios
RER/RQ

Kcal/liter O2

Fat %

Carb %

1.00

5.047

0

100

0.98

5.022

6

94

0.96

4.997

12

88

0.94

4.973

19

81

0.92

4.948

26

74

0.90

4.928

32

68

0.88

4.900

38

62

0.86

4.875

47

53

87

0.84

4.850

53

47

0.82

4.825

62

38

0.80

4.801

68

32

0.78

4.776

74

26

0.76

4.752

81

19

0.74

4.727

88

12

0.72

4.702

94

6

0.70

4.686

100

0

VO2 and VCO2 are measured via indirect calorimetry, and REE is calculated automatically
continuously by computer. This provides a relatively inexpensive, minute-by-minute, accurate
estimation of REE.
Also, we can use RER to determine the ratio of different substrates used to see how much
glucose is being utilized vs. lipid. For example, an RER of 0.7 would indicate that fat is
primarily being used where an RER of 1.00 would indicate glucose is the primary substrate as
illustrated by the following equation:
To calculate the RER, we use:
RER = (VCO2/ VO2)
If CHO is completely oxidized to CO2 and water, then the relationship is as follows:
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6 O2 + C6H12O6  6 CO2 6H2O + 38 ATP
If lipid is completely oxidized to CO2 and water, then the relationship is as follows:
C16H32 + 2302  16CO2 + 16H2O + 129 ATP, RER = (16CO2/23O2) = 0.70
If RER goes above 1.00, it is typically due to increased H+ production from a shift in the
bicarbonate buffer system. Excess H+ is expired and causes this shift in RER. Before these
additional H+ ions are expired, they can react with oxygen creating SO, or OH- and shift the ratio
of pro and antioxidants to favor oxidative stress.


Treatments for Diabetes
Diabetes is a chronic disease that requires care in treatment and alterations of lifestyle.

Eighty-five percent of Americans with diabetes are either taking oral medication or using insulin
(National Institute of Health Sciences). However these are not the preferred methods for
diabetes control. The American Diabetes Association recommends a strict diet with specific units
of measure combined with regular exercise. Only when these are not effective for completely
regulating an individual’s diabetes do we see the need for oral medications or insulin.


Outline for Literature Review
The current review of literature will be organized in the following way. First, there will be

an overview of diabetes, glucose transport, insulin resistance, and some etiologies leading to the
disease. Second, there will be an overview of the research on oxidative stress in healthy
individuals' resting metabolism. It will consist of the role of insulin, the effects of insulin
sensitivity on substrate utilization, the effects of both of these on oxidative stress, including
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metabolic bi-products and consequences, the role of SOD and catalase as antioxidants, and the
effects of oxidative stress on resting metabolism.
After a complete explanation of oxidative stress in resting metabolism in healthy individuals,
oxidative stress in resting metabolism in DMII will be discussed. This section will be organized
similarly to the previous section, except special focus on issues related to DMII will be the main
focus, including reduction in insulin sensitivity, reduced glucose uptake, difficulty with betaoxidation, and increased lipid peroxidation. An overview of measurement tools for both short
and long term glucose monitoring will be discussed. Lastly, consequences of altered oxidative
stress and insulin sensitivity in person with DMII will be discussed, including both vascular and
metabolic.
The fifth chapter of this review will deal with the influences of physical activity on fasting
oxidative stress in DMII. Previous studies covered will include cross-sectional designs in which
active and inactive diabetics are tested, and intervention studies in which physically inactive
diabetics are tested, exercise trained, and then re-tested. One of the measures of importance is
insulin sensitivity that increases with increased physical activity, which would also include
improved glucose clearance via enhanced GLUT-4, insulin-insulin receptor binding, and postreceptor signaling. Secondary to that is the improved triglyceride clearance via a reduced
chylomicron-triglyceride half-life enhanced lipoprotein lipase activity, and very importantly,
increased antioxidant up-regulation and effectiveness. Some of these antioxidants include SOD,
catalase, and glutathione and glutathione peroxidase. Other benefits that will be examined will
be enhanced short-term glucose regulation, increased oxidative stress/damage protection, and
possible substrate utilization shifts. One way of measuring this shift in substrate utilization is via
RMR and indirect calorimetry as displayed via RER. With this enhanced short-term glucose
90

regulation and possible shift in substrate utilization, we also will examine the long-term glucose
regulation as measured by Hba1C.
Overview of insulin resistance and metabolic pathway functions in diabetes


What is type-2 Diabetes?
T2D is the most common metabolic disease in the world, and it is rapidly increasing its

numbers [10]. Although all of the likely causes of this disease are unknown, insulin resistance is
an early symptom and a leading predictor of the development of T2D. It is characterized by
reduced insulin-stimulated glucose uptake and later by decreased glucose-stimulated insulin
secretion (GSIS) from pancreatic beta cells [10-12]. In order to understand T2D and insulin
resistance more fully, it is first important to first understand how glucose is transported,
especially into skeletal muscle.
Glucose Transport
Glucose is used as a major energy source in most cells of the body. As it is a large molecule,
transportation of glucose is required for it to get into the cells. There are three class-one glucose
transport proteins (GLUTs) in the human body: GLUT1, GLUT 3, and GLUT 4. These are
considered high affinity glucose transporters. Of these, a brief description of GLUT 1, 3, and 4
will follow, along with a more in-depth description of GLUT 4 which is insulin-dependent for
activation.
GLUT 1 is found in most cells, but the highest concentrations are found in erythrocytes,
kidney, colon, and cells of blood-tissue barriers (like blood-brain barriers) [13] and has a low
Km(1-2mM)1for glucose. GLUT 1 exists as a homotetramer with interaction between two GLUT
1 dimers, and within each dimer, one subunit has an exofacial site exposed while the other has a
1

Km is the substrate concentration that gives half maximal velocity of an enzymatic reaction. The higher
the Km the lower the affinity.
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cytoplasmic sugar binding site accessible [14]. GLUT 1 is considered primarily responsible for
non-insulin dependent basal glucose transport [15].
GLUT3 receptors are found mainly in neurons, placenta, and testes and have a low Km for
glucose. The most significant function of this transporter is glucose transport into neurons [16].
This transporter, like GLUT1, does not require insulin. The specific function in the brain of this
transport protein is to provide glucose to the neurons of the brain, as opposed to GLUT1, which
transports glucose through the blood brain barrier [17].
GLUT4 receptors are of more interest for this review because they are located in skeletal and
cardiac muscle, have a low Km for glucose, and are the only glucose transporters activated by
insulin. Unlike the other transport proteins discussed, GLUT4 proteins are sequestered under
basal conditions into specialized storage vesicles within the cell’s interior. GLUT4 receptors
translocate between the cell membrane where they are able to transport glucose into the cell, and
their intracellular storage compartments with increases and decreases in insulin respectively [18].
A more complete discussion of GLUT4 receptor translocation is in order. However, since it is
activated by insulin, we must first understand the role of insulin in order to understand GLUT4
translocation.


Role of Insulin
Insulin is secreted by pancreatic β cells and performs several important functions ranging

from glucagon regulation to glucose transport via activation of GLUT4. Activation of insulin
receptors on the cell membrane is the first step in insulin-stimulated GLUT4 translocation and
insulin-stimulated glucose uptake.
In order for insulin to affect GLUT4 translocation, insulin binds to the transmembrane insulin
receptor activating a series of protein cascades and triggers a large increase in the rate of GLUT4
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vesicle exocytosis and a small decrease in the rate of internalization by endocytosis. This insulinmediated increase in exocytosis is the major step for GLUT4 translocation [18]. When the
insulin receptor is (1) activated by insulin, it (2) triggers tyrosine phosphorylation of the IRS
family of proteins which (3) engage the SH2 domain of the PI3-kinase. The PI3-kinase (PI3K)
then (4) produces PIP3 which (5) stimulates kinase activity of PDK and (5) reacts with PKB to
(6) stimulate the production of a more efficient (unknown) substrate. The PDK created in the
first step of the two step (5) processes, then (6) stimulates kinase activity of PDK which then (7)
phosphorylates the lambda and zeta family members of the PCK family of proteins. These two
PCK proteins then (8) induce GLUT4 translocation to the cell membrane for (9) transport of
glucose into the cytoplasm [18]. A schematic of this that follows was adapted from one by
Watson, et al in 2001 [18].

(Watson, R.T., Recent Progress in
Hormone Research,
2001)
FIG. 1, Schematic model for the role of PI 3-kinase in insulin-stimulated GLUT4 translocation. Following
GLUT4 protein synthesis in the endoplasmic reticulum and processing through the Golgi apparatus and the tramGolgi network (TGN), the GLUT4 protein is localized to both tubulovesicular bodies and small cytosolic vesicles
scattered throughout the cytoplasm. Activation of the insulin receptor induces the tyrosine phosphorylation of the
IRS family of protein substrates that, in turn, engages the SH2 domains of the p85 PI 3-kinase regulator subunit. The
activation and/or localization of the PI 3-kinase generates the formation of phosphatidylinositol(3,4,5)trisphosphate
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(PIP3). PIP3 stimulates the kinase activity of phosphoinositide-dependent protein kinase (PDK) and interacts with
protein kinase B (PKB) to make it a more-efficient substrate. In addition, PDK can phosphorylate and activate the
atypical protein kinase C (PKC) family members, zeta and lambda.

In diabetes, there is a significant decrease in the ability of insulin to stimulate the
translocation of GLUT4 to the cell membrane. This decreased sensitivity to insulin is a major
cause in the increases in both fasting and postprandial blood glucose. While there are likely
several causes for this decreased sensitivity that we know of, none are completely understood.
Factors affecting insulin sensitivity
Since diabetes is not caused by any one single problem, several different conditions have
been linked with the onset of diabetes. While a mutation in the insulin receptor gene has been
identified as a likely candidate for the onset of type I diabetes [19], recent evidence suggests that
oxidative stress [20] is a more likely pathogenic mechanism that leads to beta cell degradation in
T2D. In addition, defects in insulin signal transduction, gene expression, muscle glycogen
synthesis, and accumulation of intramyocellular triglycerides (IMCT) are also associated as
potential mediators of insulin resistance [11, 21-25].
While there are several mechanisms that lead to the development of T2D, there are also
several ways to help counteract the decrease in insulin sensitivity. For example, weight loss
(specifically a decrease of abdominal adiposity) and reduced abdominal adiposity [26] have been
linked to increased insulin sensitivity. Similarly, aerobic fitness (VO2max) has a strong negative
association with insulin sensitivity. However, with a high level of aerobic fitness we also see
increases in intramyocellular triglyceride (IMCT) content. Elevated IMCT is also highly
associated with insulin resistance (IR) if a high VO2max is not also present [27, 28]. The exact
mechanisms that seem to aid in insulin sensitivity with increased IMCT are not yet known.
However, the changes in insulin sensitivity have been shown to affect metabolic energy sources,
and vice versa.
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Energy sources
Insulin resistance and diabetes are associated with a shift in metabolic substrate use,

including decreased glycogen utilization, and high lipolytic rates in obese individuals. Using
contemporary stable isotope methods, Boon (2007) found that whole body fat oxidation rates
were significantly higher in long-standing T2D patients vs. age, weight, and oxidative capacity
matched controls [29]. These changes were attributed to the increase in nonesterified fatty acid
(NEFA) circulating through the bloodstream. This is contradictory to other studies that indicate
similar whole-body fat oxidation between T2D patients and control groups [30-35]. Unlike these
studies, Boon reported that despite elevated plasma glucose appearance rates, the total
carbohydrate oxidation rates in T2D were reduced as compared with controls [29].
The differences between Boon’s study and the previous studies mentioned were the use of
stable isotope methods and muscle biopsies as compared with isotope tracer and forearm balance
techniques in the previous studies. Also, the long term T2D patients in this study differed from
the previous studies in that these individuals no longer exhibit compensatory hyperinsulinimia.
With the lack of the body’s ability to compensate for being insulin resistant by producing vast
amounts of insulin, the mitochondria may be able to adapt to using FFA as an alternate energy
source. This could explain the differences between Boon’s results in 2007 indicating elevated
whole-body fat oxidative and the previous studies that show no changes for fat oxidation in
diabetics compared to controls.
The uptake and subsequent metabolic fate of excessive fatty acids in skeletal muscle of
persons with advanced T2D may be responsible for fatty acid-induced changes in muscle insulin
action [36]. The higher uptake of fatty acids than their subsequent metabolism results in fatty
acid intermediates in the cell, for example, ceramide, diacylglyceride (DAG), and long chain
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fatty acyl CoA. These intermediates increase insulin resistance through pro-inflammatory/stress
pathways [36] and increased serine-kinase activation [37].
However, there is an overall lack of agreement on disturbances in substrate metabolism in
people with T2D. For example, basal metabolism of whole body lipids in T2D has been reported
to be both elevated [29] and similar to [29, 31, 32, 34, 35, 38] healthy lean controls. Two key
factors causing discrepancies here could be different stages of progression of the disease, and
differences in body fat content in the different studies' participants.
It is difficult to know whether the resistance to insulin causes a shift in substrate utilization in
T2D, or the shift leads to the development of insulin resistance and T2D. However, we do see a
genetic link in the shift of fasting substrate utilization with the decrease in insulin sensitivity.
Both diabetic and pre-diabetic muscles have reduced oxidative phosphorylation gene expression
[39]. Several genes regulating lipid transport and metabolism are severely decreased in T2D and
pre-diabetes, including 3-hydroxyacyl CoA dehydrogenase which catalyzes the oxidation of L-3hydroxyacyl CoA by NAD+ in beta oxidation, mitochondrial 3,2-transenoyl-CoA isomerase
(which transforms 3-cis and 3-trans intermediates to 2-trans-enoyl-CoA compounds in
unsaturated fatty-acid beta oxidation), and 2,4-dienoyl CoA reductase 1(also involved in
unsaturated fatty-acid beta oxidation) [39]. In addition, Patti et al. [39] also found that
expression of several glycolytic and tricarboxylic acid cycle genes were significantly decreased
in these populations, including glucose phosphate isomerase (catalyzes the conversion of
glucose-6-phosphate into fructose 6-phosphate), fructose 1,6, bisphosphatase 2 (which opposes
phosphofructokinase in gluconeogenesis), pyruvate kinase (catalyzes the transfer of a phosphate
group from phosphoenolpyruvate (PEP) to ADP, yielding pyruvate and ATP), pyruvate
dehydrogenase A1 (catalyzes conversion of pyruvate to Acetyl CoA), α-ketoglutarate
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dehydrogenase (in the citric acid cycle, it catalyzes conversion of α-ketoglutarate to succinyl
CoA), and succinate dehydrogenase B (important in both the citric acid cycle, and the electron
transport chain). However, Patti et al. {Patti, 2003 #97}had a relatively low number of subjects
and used microarray data which sometimes gives false positive tests. These factors may
confound the results of the study.
In addition to the findings of Patti et al. {Patti, 2003 #97}, other non-genetic studies also
illustrate that T2D and pre-diabetes manifest decreased glucose oxidation and storage, and
reduced activity of tricarboxylic acid cycle, β-oxidation, and electron transport enzymes [38].
For example, pro-inflammatory cytokines such as TNFα, which act through the serine/threonine
phosphorylation of insulin signaling pathways, have also been associated with reduced insulin
sensitivity [40]. Causes for increases in pro-inflammatory cytokines are numerous, and beyond
the scope of this review. Though metabolic energy sources can be regulated by many
mechanisms, the availability of substrate is a major factor in both substrate utilization and
mechanisms responsible for the onset of insulin resistance.


Metabolic substrate availability on insulin resistance
With the increase of NEFA and other circulating long-chain FFA seen with diabetes come

the risk of elevated lipotoxicity and insulin resistance. Lipotoxicity refers to the process leading
to end-organ damage or dysfunction following excess exposure to fatty acids [41]. The
associated insulin resistance that comes with elevated NEFA is likely to be caused by impaired
glucose transport at the level of the plasma membrane by deficiencies in insulin activation of
IRS-1 associated PI-3-k activity in skeletal muscle [42]. This reduction of insulin activation of
IRS-1is thought to be due to a block in insulin receptor tyrosine phosphorylation of IRS-1in
GLUT4 translocation [37]. In addition to NEFA affecting insulin sensitivity at the level of the
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insulin receptor, accumulation of such lipids as NEFA and DAG may also lead to activation of
nPKC which, in turn, also reduces insulin-stimulated GLUT4 translocation [41], however the
mechanisms of which are not completely understood.
In addition to circulating long-chain fatty acids seen in T2D, intermyocellular triglycerides
(IMCT) are also sharply elevated. While this is a beneficial adaptation in endurance athletes, it is
detrimental to the function of the mitochondria in T2D. The overabundance of IMCT seen in
diabetes has been linked with increased ROS-induced peroxidation, which in turn causes damage
to the mitochondria [43], making IMCT use less likely to occur and perpetuating the cycle of
increased NEFA and IMCT, reduced insulin resistance, elevated ROS and increased
concentration of fatty acyl CoA’s, DAG, and ceramides. This may be responsible for the
reduced expression of mitochondrial electron transport system genes seen in T2D which causes
NADH accumulation in beta cells, thereby halting the tricarboxylic acid cycle on one hand, and
on the other hand, facilitating anaerobic glucose metabolism [44]. This may be related to the
changes in the Futile cycle (glycerolipid/free fatty acid, or GL/FFA cycle) from decreased
expression of GyK in adipocytes. This leads to a shift from the oxidative futile cycle to anaerobic
futile cycle (insulin-independent) which creates pre-cursers for gluconeogenesis in the liver,
resulting in an increase in blood glucose. It is possible that the increases in IMCT seen in
diabetes would NOT occur if ROS did not cause mitochondrial dysfunction, and vice versa.
Not only is there problems with elevated IMCT in T2D, but there is also decreased glycogen
loading into skeletal muscle. Shulman et al. [45] found that muscle glycogen synthesis was
reduced in diabetics by as much as 50%, and that this is a major contributor for insulin resistance
under hyperinsulinemic and hyperglycemic conditions. Using 13C and 31P MRS, Morino et al.
[42] argued that the rate of insulin-stimulated muscle glycogen synthesis was due to a reduction
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of glucose transport into the muscle, and therefore suggest that decreased glucose conversion to
glycogen slows glucose transport, and is responsible for increased insulin resistance.
Contradicting this theory is the work of Cline et al. In their study, rats treated with a glycogen
kinase-3 inhibitor (for more activated glycogen synthase) still experienced fat-induced insulin
resistance in skeletal muscle [46]. This would indicate that there are likely several confounding
mechanisms that lead to the development of insulin resistance. Therefore, multiple approaches in
studying the causes of insulin resistance are needed so that better and more individualized
treatments can be developed.


Treatments of insulin resistance
Increasing insulin sensitivity is a key for controlling T2D. Weight loss, medication, diet and

exercise have been shown to decrease insulin resistance in T2D. Studies have shown that weight
loss, or even a change in dietary composition not only improves insulin sensitivity, but also
lowers blood triglycerides and ROS as well [47]. It is not clear which is affected first, the
triglycerides or the ROS. Nonetheless, dietary regulation is the first step required to regulate
blood glucose and improve insulin sensitivity.
Often when diet and weight loss are not enough to regulate blood glucose, medication is also
given. For example, there are available medications (e.g. thiazolidinediones, TZDs) that act as
ligands for nuclear receptor peroxisome proliferator-activated receptor (PPAR)-γ, markedly
induce adipocyte glycerol kinase (GyK) gene expression and subsequently lowering free fatty
acid (FFA) and helping to control insulin sensitivity. Also, Ca++ release from muscle
contraction during exercise reduces PGC-1α production, which aids in insulin sensitivity and
decreased incidence of diabetes [48]. A combination of medication, diet/weight loss, and
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exercise are often prescribed in different combinations to better control insulin resistance and
subsequent blood glucose levels.
Separate from diet and weight loss, exercise has also been shown to improve several markers
in diabetics, however combining dietary regulation with regular exercise has been shown to be
most effective. For example, Roberts et al. [47] shows that an unrestricted diet of low-fat and
high fiber in combination with exercise significantly lowers ROS, blood pressure, cholesterol,
and vastly improve insulin sensitivity. A more in-depth discussion on the effects of exercise on
resting oxidative stress and insulin resistance will be given in a later chapter.


Measurement Tools
With such long-term problems as peripheral neuropathy, blindness, amputation, and death,

there is a need to closely monitor glucose levels in diabetes. Luckily, at-home testing is readily
available and easy to use. For example, Roche Accu-Chek, Prodigy Voice and One-Touch make
some of the more common glucose monitors that can be purchased for approximately $15-$100.
Each requires a small amount of blood for analysis. A lancing device is used for finger and
forearm pricks. Glucose monitors and lancets use disposable test strips and needles respectively.
Typically, results are available in just a few seconds. These devices will indicate current blood
glucose levels, and are helpful in that they enable people with T2D to make adjustments (e.g.
like eating or using insulin) to better control their blood glucose levels.
A better indication of blood glucose management can be determined by using a long-term
glucose recall test called hemoglobin a-1c (Hba1c). Hba1c is a test that measures the amount of
glycated hemoglobin in the blood. Glycated hemoglobin is a substance in red blood cells formed
when blood sugar (glucose) attaches to hemoglobin. In essence, it is a three month glucose recall
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test and is very important in determining how well each person is able to control his/her blood
glucose over the course of two to three months.
In addition to testing for blood glucose levels, diagnostic tests are important in determining
the likelihood that a person will develop T2D, or has insulin resistance. Diagnostic testing for
T2D is typically conducted by performing either an insulin sensitivity test, or a glucose tolerance
test. Insulin sensitivity testing utilizes simultaneous intravenous insulin and glucose infusion in
set doses. The insulin is administered immediately prior to glucose infusion in a small, set dose.
Glucose is then dripped intravenously with careful watch over the quantity. The basis of this test
is to determine how much glucose has to be administered in order to overcome the previously
infused insulin and raise the blood glucose to a pre-determined cut-off level. This directly
measures how sensitive each person is to insulin. However, this is a lengthy, expensive, and
potentially dangerous test that requires a careful supervision of a physician.
An easier, safer and less expensive diagnostic test is the oral glucose tolerance test (OGTT or
GTT). For this test, the patient has their blood glucose measured in a fasted state using a simple
glucose meter mentioned above. Then a pre-measured GT beverage (fruit punch) is given and
consumed within 2 minutes. Glucose is checked at regular intervals for up to three hours. The
cutoff for blood glucose levels to indicate gestational T2D are: 180mg/dL after 1-hour,
155mg/dL after 2-hours, and 140 mg/dL at 3-hours.
Aside from insulin and glucose testing, resting metabolism can easily be measured via direct
or indirect calorimetry. Direct calorimetry involves being in a closed-in room where the slightest
changes in temperature can be accurately measured. The increase in heat production can be
calculated as the amount of oxygen used to burn a certain number of calories. This is a very
expensive and time-consuming method. A less expensive and fast alternative is indirect
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calorimetry. With indirect calorimetry, the fasting person maintains a lying position with a
vented hood over his/her face. The hood is connected to a metabolic gas analysis cart which
measures the difference between the [oxygen and CO2] breathed in and exhaled, calculating
amount of O2 consumed and CO2 produced. With this measurement, respiratory exchange ratio
(RER: the ratio of metabolic substrates burned; fat vs. sugar) and energy expenditure (EE) can be
calculated. Energy expenditure (EE), or resting metabolic rate (RMR) can be calculated with this
method. Lower RMR indicates burning less energy at rest, and a lower RER indicates that more
fat is being burned as compared with glycogen. For example, a RER close to 0.7 indicates almost
all fat is being utilized, but the closer to 1.0 RER is, the more CHO is burned.


Summary
In T2D, we see decreases in insulin-stimulated glucose uptake leading to possible decreases

in GSIS. The initial etiology of T2D is not completely understood. This is likely because there is
not a single causative factor leading to the development of T2D, but more likely there are
several. Of these possible causes, genetics most certainly cannot be ruled out. However, other
possible causes are likely such as poor diet and exercise habits. These factors often lead to
obesity, which has been linked with impaired whole-body beta-oxidation, increased NEFA, and
insulin resistance. Lipotoxicity, inflammation, and oxidative stress have all been suggested as
mechanisms that are part of a deleterious cycle of mitochondrial dysfunction leading to increased
oxidative stress, which in turn has been linked with increased lipotoxicity and inflammationboth of which can lead to increased ROS production and insulin resistance. In fact, since there
are several likely causes of T2D, it may be beneficial to think of T2D not as a disease so much as
a common syndrome consisting of similar symptoms stemming from multiple causes. With this
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concept, it is easier to understand the need for different approaches in discovering the cause and
solution to the world’s fastest growing epidemic.
Overview of Oxidative stress in Resting Metabolism in Healthy Individuals


Pro- and Antioxidant Overview

Pro-oxidants and antioxidants are formed as a normal product of aerobic metabolism.
However, when production rates of pro-oxidants are elevated, they may exceed the ability of
body’s antioxidant defense system to neutralize the oxidants as they are formed. When this
happens, the shift towards pro-oxidants may result in cellular damage. This damage is called
oxidative stress [49].
Of the pro-oxidants, some of the most abundant are reactive oxygen species (ROS) and
reactive nitrogen species (RNS). However, the focus of this review is on ROS. The major ROS
oxidants are ultimately reduced to water through a series of intermediate steps, each of which
forms an oxidant. The oxidant chain is as follows: superoxide  hydrogen peroxide  hydroxyl
radical  water. If the ROS is not neutralized to form water, oxidative damage occurs.
The superoxide anion (O2-) is the primary ROS molecule, and is formed through metabolic
processes using oxygen. This superoxide production mostly occurs inside the mitochondria when
the mitochondrial electron transport chain leaks small numbers of electrons to oxygen
prematurely [50, 51]. It is highly reactive with an extremely short half-life of a fraction of a
second and can react with different organelles inside the cell causing oxidative damage, or with
other molecules and metals to form secondary ROS molecules [52]. However, the specific halflife of any ROS molecule is dependent upon the concentration of the opposing antioxidants
present. The reduction of superoxide by biological antioxidant superoxide dismutase (SOD)
forms a less reactive oxidant, hydrogen peroxide (H2O2). Since this oxidant is less reactive (it has
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a half-life of several seconds) and permeable to the cell membrane, it is therefore able to travel to
more distant locations causing oxidative damage away from the site of production. Since H2O2 is
lipid permeable, it not only can cause intracellular protein and DNA damage, but can also initiate
fatty acid peroxidation [53]. However, H2O2 can also be reduced further to form yet another
radical, the hydroxyl radical (.OH ). .OH is highly reactive with an extremely short half-life of a
fraction of a second [54] and is produced when hydrogen peroxide is reduced by intracellular
iron (Fe2+ + H2O2  Fe3+ + .OH + OH-) [55].
These oxidants are neutralized by enzymatic antioxidants produced in the body, superoxide
dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) [49]. With each step,
superoxide is reduced one step closer to water. However, each step until then yields a potentially
dangerous oxidant capable of causing cellular damage both at the site of origin, and further
downstream. Since ROS is naturally formed from the metabolic processes, certain factors of
metabolism affect ROS production, and vice versa.


Effects of oxidative stress resting metabolism
Resting metabolism in healthy individuals can utilize glucose and glycogen more readily

through the citric acid cycle because they are sensitive to insulin. During the citric acid cycle,
NAD accepts a H+ ion to form NADH which then donates a H+ to the electron transport chain
where oxygen is the final acceptor, creating H2O. From start to finish, glycolysis, intermediate
step and the Krebs Cycle generate: Glycolysis (2 pyruvate, 2ATP, 2 NADH), intermediate step
(x2) (2acetyl CoA, 2 CO2, 2 NADH), Krebs Cyle (4 CO2, 2 ATP, 6NADH, 2FADH+H). As
glucose and glycogen are metabolized, depleted stores are replaced by the breakdown of fat
(lipolysis) [56]. The result of this efficient resting metabolism is a small production of ROS via
the electron transport chain. However, if the system becomes less sensitive to insulin, as in
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disease states like diabetes, metabolism relies more heavily on fat metabolism instead of glucose,
resulting in a higher concentration of IMCT, increased ROS production, elevated markers of
inflammation, higher blood-glucose levels, and further insulin insensitivity.
The low production of ROS in healthy individuals can serve several functions. As a product
of normal cellular metabolism, ROS can actually aid the body’s defense against infection and in
the induction of a mitogenic response [55]. However, with mitochondrial dysfunction, the
harmful effects ROS overproduction can lead to oxidative stress as discussed previously. While
ROS production is not normally thought to be high enough to induce harmful levels of oxidative
stress for most healthy individuals, it does exist in limited quantity at rest and can potentially
lead to oxidative stress, especially when metabolic circumstances change to favor ROS
production.
Elevated ROS production and pathologic levels of oxidative stress are typically present when
proper mitochondrial function is disrupted [57]. The delicate balance between beneficial and
deleterious effects of ROS is termed redox regulation [55]. Maintaining this redox regulation
balance can aid in many needed biological processes, including immune function. However,
shifting away from redox regulation towards increased ROS production and oxidative stress can
lead to many pathologic conditions, including T2D, cancer, cardiovascular disease and aging
[55].
Some of the conditions that increase resting ROS production include cigarette smoking [58],
improper micro and macro nutrient intake [49, 59], stress [60] and gender [59]. With smoking or
overeating, chronic stress is placed on the metabolic system causing damage. Unlike exercise,
this stress is often relentless, never allowing the body to adapt and overcome these stressors. Diet
and exercise have also been shown to significantly reduce plasma oxidative stress and
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cholesterol [47]. This study [47] also shows that increased exercise and a diet of reduced fat and
increased fiber affected not only resting oxidative stress, but also reduce blood pressure and
cholesterol, and increase insulin sensitivity. Thus, the contribution of a healthy diet and regular
exercise are important for maintaining not only typical health markers such as blood pressure and
cholesterol, but also healthy redox regulation.


Oxidative Damage
With high enough concentrations, ROS can play a key role in mediation of damage to

cellular structures, nucleic acids, lipids, and proteins [61]. The hydroxyl radical reacts with all
DNA components, causing damage to both the purine and pyrimidine bases and the deoxyribose
backbone. Oxidative damage to DNA causes permanent modification of genetic material and
represents the first step towards mutagenesis, carcinogenesis, and ageing [55].
ROS can also react with polyunsaturated fatty acid residues of phospholipids leading to lipid
peroxidation, with malondialdehyde (MDA) being the final product of this peroxidation [61-64].
MDA is thought to be both mutagenic and carcinogenic [52, 55]. In addition to mutagenic MDA
production, lipid peroxidation can also lead to 4-hydroxy-2-nonenal (HNE) which is weakly
mutagenic, but is a major toxic product of lipid peroxidation. Furthermore, increases in lipid
peroxidation have long been associated with decreased function of glucose-6-phosphatase [65]
which may lead to increased hyperlipidemia [13], which as previously mentioned is one of many
pre-cursors to oxidative stress and insulin resistance. Increased lipid peroxidation has also been
implicated in the promotion and progression of carcinogenesis and the development of
atherosclerosis and increased inflammation [66, 67].
Since proteins are a major component of most biological systems, they also make up a highly
concentrated target for oxidative damage. Increased protein oxidation has long been associated
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with aging and age-related diseases, along with decreased function of many biological enzymes
[68]. Of the different sub-units that make up proteins, the cysteine and methionine residues of
proteins are most susceptible to oxidation by ROS [69]. Cysteine residue oxidation leads to the
formation of disulphides between protein thiol groups (-SH) and low molecular weight thiols, for
example, GSH (S-glutathiolation). These are formed when amino acids that form protein are
broken apart, and can be measured as a marker of protein peroxidation. Some of these free amino
groups that result from ROS oxidation of protein can react with carbohydrate to form advanced
glycation end products (AGEs) [70]. Most AGEs are unstable, reactive compounds that can
cause further molecular damage as previously discussed. Furthermore, oxidation of a protein
induces inactivation of that molecule from its original function and also leads to protein
backbone fragmentation.


Role of SOD, Catalase and GPX
The different ROS molecules react at different rates and can cause various kinds of cellular

damage both near and far from the site of production if left undeterred. That is why
understanding and regulation of ROS is vitally important. Keeping ROS in a healthy balance
requires the constant influence of other biological processes. These processes require the help of
the antioxidant system.
The three major antioxidants responsible for keeping ROS in check and regulating oxidative
balance are glutathione peroxidase (GPx), SOD, and catalase CAT. GPx and CAT have many
functions that protect against oxidative stress. Among them are the ability to scavenge the
hydroxyl radical directly, and detoxifying H2O2 and lipid peroxides [55]. SOD acts to neutralize
ROS (O2-, H2O2, OH-) [71]. It scavenges superoxide and reduces it to H2O2 so that GTx and CAT
can further reduce them to water [71]. This is a relatively efficient method in most healthy
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individual. However, in cases involving smoking, stress, high-intensity exercise and a high-fat
meal, OH- is often produced faster than SOD can work, leading to increased oxidative damage.
OH- is an extremely dangerous oxidant that can react with almost anything in a biological
system, especially DNA [72], therefore its reduction to H2O2 is vital.
H2O2 is a dangerous radical because it has a long half-life (seconds) and can pass through the
mitochondrial membrane and inflict intra-cellular damage away from the site of formation [55].
However, H2O2 is often effectively broken down by CAT and GPx to form H2O. In this respect,
a long half-life is a hidden benefit in that it can remain stable long enough for CAT and GPx to
reduce it further. However, inability to efficiently neutralize oxidants leads to oxidative damage,
which in apparently healthy individuals has been linked to endothelial dysfunction [60] and the
onset of diabetes [73]. The overall effect of the antioxidant system, SOD, GTx, and CAT are to
reduce oxidative stress to form water, and maintain normal biologic levels of ROS and help
prevent oxidative stress-induced deleterious conditions such as cancer, cardiovascular
dysfunction, and insulin resistance as seen in diabetes.


Measurement Tools for Oxidative Stress
There are several ways in which to measure oxidative stress. Traditionally we look for

markers of damage. For example, Thiobarbituric Acid Reactive Substances (TBARS), DNA
adducts, N-nitroso compounds, Malondialdehyde (MDA), and 1-hydroxypyrene are a few. More
recently, it has become possible to measure ROS directly in RBCs through a spin trap method.
These measurements typically give higher values than damage markers, most likely because not
all the ROS measured in the spin trap causes oxidative damage. Oxidative stress occurs on the
cellular level, so evidence of oxidative stress and damage can be seen in muscle, adipose tissue,
and blood. Performing muscle or fat biopsies is an extremely invasive procedure that requires
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expertise; therefore measurements from blood are most often done using commercially available
ELISA kits. Since O2- can either oxidize or reduce, assays have been designed to either oxidize
compounds like epinephrine or tiron, or to reduce tetranitro methane or cytochrome c [71].
At rest, healthy individuals utilize oxidative pathways to breakdown both glucose and fat to
generate energy, ending with the electron transport chain. With the effects of insulin, there is
ample ability to use glycogen for this process [49], though beta-oxidation is used most at rest.
Resting metabolism can use different substrates for energy, including triglyceride or glucose.
Burning triglyceride is thought to be preferred. However, to be able to use triglycerides, certain
proteins are required, including carnitine, and Uncoupling protein 3 (UCP3). Carnitine is used
as a transport (which transports long chain FFA like 18 C steric acid, the most commonly stored
length TG) for fat into the mitochondria (carnitine transferase) to be oxidized to produce energy.
UCP3 for example, is another member of the mitochondrial carrier superfamily. Based upon its
high homology with UCP1, UCP3 has been suggested to play important roles in regulating
energy expenditure, body weight and thermoregulation [60].
Typically, fat is the primary source for energy at rest; however there are reasons that CHO
would be used more in resting metabolism. For example, if a person is in a state of positive
energy balance (consuming more calories than he/she burns), there is a shift to utilize more CHO
and store more fat. Also, in certain disease states breakdown of fatty acid is inhibited, and CHO
is the main sources for aerobic metabolism at rest.


Summary
In summary, healthy individuals typically have normal levels of insulin production, and

sensitivity. This helps upload and utilize glucose as part of a normal healthy metabolism. ROS
and other pro-oxidants are formed from aerobic metabolism, and serve both positive and
negative functions in the body. Antioxidants are vital to the removal of oxidizing factors such as
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ROS (O2- OH- and H2O2) and helping maintain a healthy oxidative balance in the body, called
redox regulation. When pro-oxidants are more abundant than antioxidants can handle, the
balance shifts towards the formation of pro-oxidants. We call this shift oxidative stress.
Oxidative stress is kept at low levels by a healthy antioxidant system including, but not
limited to, SOD, glutathione peroxidase and catalase. Several factors act to increase levels of
ROS production in healthy individuals, including smoking, improper diet, obesity and lack of
physical activity. When adverse factors come into play, such as oxidative stress, insulin
sensitivity decreases leading to chronic health problems, including cardiovascular disease and
diabetes.
Overview of type-2 diabetes, including oxidative stress in resting metabolism and its effect
on insulin resistance

Since diabetes is a metabolic disorder, great effort has gone into isolating the mechanism(s)
responsible for the development of diabetes. Many studies have shown increased oxidative
stress in association with insulin resistance (IR) and T2D. In 2003, Brownlee developed a
unifying hypothesis that overproduction of hyperglycemia-induced mitochondrial superoxide
uncouples protein 2, which eventually leads to IR [74]. With diabetes, we not only see increased
oxidative stress with hyperglycemia, but also from significantly elevated levels of NEFAs and
other long-chain circulating fatty acids. This elevation of long-chain fatty acids can lead to a
reduced proton gradient in the inner mitochondrial space leading to mitochondrial dysfunction
and impaired oxidative capacity, matrix swelling and enhanced production of ROS [41]. Since
ROS production can be caused by several different pathways, it is important to consider the
development of T2D as a result of one of several potential metabolic processes gone astray
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including high mitochondrial fatty acid oxidation, endoplasmic reticulum (ER) stress or elevated
TNFα. Any of these can also activate inflammatory pathways (JNK-AP1, and IκKβ-NFκB)
leading to increased cellular inflammation, which in turn leads to increased ROS production
[75]. This section is an attempt to reconcile the various ways that ROS production at rest leads to
IR in T2D.


Role of oxidative stress  resting metabolism
Oxidative stress is produced mostly from aerobic metabolism in the electron transport chain.

However, when looking for specific ways in which it is produced, there are several. For example,
Complex II in the electron transport chain produces ROS in diabetes, but the question is why?
Also, high blood-glucose levels have been strongly associated with oxidative stress, but is it the
high levels of glucose that leads to ROS production and mitochondrial dysfunction, or the other
way around? In addition to high blood-glucose, high circulating FFA is also associated with
elevated oxidative stress. Similar questions arise: is it an increase in IMCT that leads to
oxidative stress, the increased FFA, or is there a metabolic problem prohibiting the efficient use
of FFA that makes these levels appear so high that could be to blame? Associated issues with
ROS production may affect metabolism, and therefore also should be considered. For example,
NADPH in circulating neutrophils produce ROS leading to potential oxidative stress. These and
other metabolism related problems will be discussed in this section.


Complex II production of ROS
It has been suggested that the main location for the production of ROS leading to oxidative

stress is the Complex II proteins within the electron transport chain of the mitochondria in
diabetes. Complex II is one of 5 protein complexes used as a shuttle to move H+ from NADH to
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molecular oxygen to form water [76, 77]. Investigating this, Yamagishi et al, (2001) used a
complex 2 inhibitor (TTFA) along with an uncoupler of oxidative phosphorylation, and saw a
significant decrease in SO production. However, blaming Complex II proteins from this research
is highly speculative because the series of projects were done in vitro, thus lacking the natural
endogenous antioxidant capacity. Also, though claims of SO production were made, it is
extremely difficult to directly measure SO because its ½ life is 10-9s. Even so, the research does
strongly suggest that Complex II is an area in diabetes where there is either higher ROS
production, or lower antioxidant capacity.


Glucose toxicity
ROS formation and IR are also associated with high levels of blood glucose over an extended

period of time. This is called glucotoxicity. In some cases, glucose auto-oxidizes, and in others, it
reacts with H2O2, iron, or copper to form a dangerous hydroxyl radical [78]. Glucotoxicityinduced ROS production can be detrimental to insulin-producing islet cells in the pancreas
because of the inherent lack of endogenous antioxidant production/availability found in
pancreatic islet cells. As a result, insulin production is decreased due to diminished beta cell gene
expression [79-81]. In addition, glucotoxicity has also been shown to diminish glucokinase gene
expression [82]. While these studies measured specific actions specifically due to high glucose,
they were in vitro and limited to acute exposure to high glucose. As such, the actual findings of
many of these studies were on glucose desensitization rather than toxicity, which would develop
after long-term exposure. Robertson et al. [79] exposed cultured HIT-T15 cells and animal
models to long-term glucose elevation. This exposure showed a strong relationship with beta cell
dysfunction in both animal models and in vitro, and was reversed when animals were treated
with glucose-lowering factors that contain antioxidants (aminoguanidine, phlorizin, and N112

acetycysteine- which lower glucose) as well as troglitazone and phlorizin which lower
triglycerides and have antioxidant capacity. Thus, based on the findings of Robertson et al. [79]
using both in vitro and animal models, it is reasonable to conclude that both glucotoxicity and
ROS were involved with beta cell dysfunction..
Robertson’s idea to conduct research on high chronic levels of glucose leading to ROS
production and oxidative stress was not novel. In fact, it was preceded by several studies
examining the effects of glucotoxicity on pancreatic islet cells. Due to their inherent low
antioxidant capacity, islet cells are very susceptible to oxidative damage, including glucose autooxidation [83-86]. The study by Wolff and Dean [86] showed that ROS-generating glucose
auto-oxidation leads to islet damage and decreased insulin production. Addition of GPx
protected the islet cells from oxidative damage in vitro with high glucose addition [87, 88]. Both
the Ihara et al. [88] and Tanaka et al. [87] specifically tested the addition of GPx on islet
oxidative damage, then inhibited GPx and found that damage increased again. However, the
Tanaka et al. [87] study was with cultured cells in vitro, which lack the complexity of human
defenses against oxidative stress under non-physiologic conditions. Ihara et al. [88] used an
animal model which, while under physiologic conditions, is unlike in humans in that the animals
were engineered to display a particular trait through ONE mechanism. Thus, it is likely that the
results from knock-out mice not be exactly duplicated in a human model. Also, these studies
tested ROS (which is extremely difficult to directly measure as the half-life is 10-9s) as a result of
glucose toxicity, a subsequent symptom in the development of diabetes. Furthermore, the
threshold for glucose levels to actually cause glucose toxicity is not currently known, so
extremely high levels of glucose were administered and were likely not of a physiologic level.
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More recently, studies have supported the Tanaka et al. (1999) and Ihara et al. (1999)
findings that pancreatic beta cells are more susceptible to oxidative damage via glucotoxicity
because of low enzymatic antioxidants (SOD, CAT, GPx) [89, 90]. These researchers work also
suggest that ROS generated from hyperglycemia activates several deleterious pathways,
including advanced glucose end-products (AGE), receptors for AGE (RAGE ), PKC, nuclear
factor κB (NF- κB), and nitrogen-activated protein kinase (MAP). Reduced insulin sensitivity
and production was reversed in both in vivo and in vitro with the addition of antioxidants,
illustrating that IR can be blunted by reducing the harmful oxidizing effects of ROS. Beta-cell
function was blunted with the addition of H2O2 in vivo, and was reversed with the addition of
vitamins E and C and lipoic acid. However, antioxidant interventions in vivo had a low sample
size and were administered for a short duration. In addition, the in vitro methods used extremely
high levels of antioxidants not found in that concentration naturally in the body. Also, these
antioxidants were not target specific, or more accurately, not made near the site of ROS
production, so in vivo they could react with numerous molecules throughout the body; thus the
results in vivo are not in full agreement with these data.
Since pancreatic mRNA damage from glucotoxicity has been suggested as a likely cause for
declining insulin secretion later in diabetes, it is important to find ways to prevent or reverse this
process. There have been studies to find mechanisms of protection that may help prevent this
from happening. In one study [91], researchers subjected rat islet cells to oxidative stress and
found that JNK, P38, and protein kinase C was activated. This activation occurred before any
decrease of insulin gene expression was noted. Over-expression of dominant-negative c-Jun
NH2-terminal kinase (DN-JNK) was shown to protect PDX-1 insulin promoting factor and
insulin gene mRNA from oxidative damage [91].These findings however, do not distinguish
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from decreased ROS production or a decrease in apoptosis. Also, since the study design was
based on cell transplants and had no quantitative measurement of apoptosis, they were not able to
distinguish between cellular protection from ROS over-production and a decrease in apoptosis.
Hyperglycemia may also lead to the upregulation of angiotensin II, a neurohumoral agent
that stimulates superoxide generation by the mitochondria [92]. This follows along with
Brownlee’s unifying hypothesis of diabetes, and also compliments the work of [93, 94]. These
researchers found that hyperglycemia leads to reductions of endogenous antioxidant activity via
suppressed taurine transporter. Unfortunately, neither Salceda [93] nor Stevens et al. [94] were
able to discover the mechanism of how taurine affected antioxidant activity, or its overall effects
on redox-regulation.


Lipotoxicity
The idea that an elevation in circulating FFA can lead to oxidative damage and insulin

resistance is a relatively new idea. There have been strikingly few studies that specifically
examine the effects of lipotoxicity on oxidative stress in diabetes. However, Carpentier wrote a
review article in 2008 about postprandial oxidative stress [41], and in it he briefly discussed the
effects of lipotoxicity. In theory, the elevated FFA leads to an increase in oxidative stress and
subsequent IR. The following is a review of the few studies focused on this concept.
Elevated FFA has been related to increases in IMCT, and both increased FFA and IMCT
have been linked to IR and oxidative stress through changes in metabolic function. For years,
evidence has indicated that increased oxidation of IMCT leads to elevated levels of intracellular
acetyl CoA and citrate which in turn inhibits pyruvate dehydrogenase and phosphofructokinase
[95]. These enzymes are crucial to glucose utilization, and their inhibition could lead to increased
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intracellular glucose making insulin-stimulated glucose uptake even less likely to occur.
However, more recently, Rosca et al. [96] described a cascade of events recognized to be one of
the most important pathways leading to the development of T2D. They suggested that
overproduction of ROS led to oxidative damage, which caused stress-related defects in oxidative
phosphorylation machinery and subsequent mitochondrial oxidation led to excess accumulation
of intracellular triglyceride in muscle (IMCT) and liver. This build-up of IMCT led to
subsequent insulin resistance [96]. Rosca et al. [96-98] showed specific pathways where oxidized
proteins (MGO) attach to mitochondria to form AGE, which inhibited renal mitochondrial
function. However, this study ignored damage leading to MGO elevation and placed focus on a
downstream mechanism instead. It would have been beneficial to probe the factors leading to the
MGO elevation associated with increases in IMCT. Also, the greatest source for metabolic
activity in the body is skeletal muscle, and the Rosca et al. [96]study focused on renal protein
and mitochondria in rats.
Aside from Rosca et al., [96], there have been studies that implied elevated FFA was one
likely cause in the development of IR, using advanced magnetic resonance spectroscopy (MRS)
technology [42]. MRS studies have shown glycogen synthesis and not hexokinase (previously
thought to be responsible for IR) was responsible for IR under hyperinsulinemic conditions.
With a decline in glycogen synthesis in diabetes, there was less glycogen available for glycolysis
to create energy in resting metabolism. Further support for decreased glycogen synthesis leading
to IR was that mice with over-expression of hexokinase were not protected from IR when a
glycogen synthase kinase-3 inhibitor was given [99]. Morino et al. [42] described the deleterious
process of how the serine kinase cascade affected insulin sensitivity (figure 1) as three processes:
1) lower insulin-stimulated IRS-2 tyrosine phosphorylation, 2) lower IRS-2-associated PI-3-k
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activity, and 3) lower AKT2 activity of the GLUT4 translocation process [42, 99]. This cascade
initiated a series of events deleterious to insulin sensitivity including a reduction of insulinstimulation of glycogen synthase activity resulting in lower hepatic glucose uptake. Also, the
reduced activity of AKT2 resulted in decreased phosphorylation of forkhead box protein O
(FOXO) making it permeable to the nucleus so it could activate transcription of
gluconeogenesis’ rate controlling enzymes (phosphoenolpyruvate carboxykinase, glucose-6phosphate phosphatase). As a consequence, the increased gluconeogenesis further exacerbated
hepatic IR and thereby caused an increase in fasting hyperglycemia [99-101]. Having the ability
to accurately measure such things in real-time with MRS can lead to exceptional work. However
these tests require the participant to lie perfectly still in uncomfortable positions for extended
periods of time, and any movement can blur the image being saved. Also, human analysis of
MRS can lead to subjective interpretation of data.
Figure 1
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Not only has elevation of FFA in both rat and human diabetics abolished insulin activation of
IRS-1-associated PI 3-kinase activity required for GLUT4 translocation, but also in DOS. Recent
indications were that IMCT metabolites, not just FFA, increased IR via a serine kinase which
phosphorylates serine on IRS-1, and this seems to have had a negative effect on insulin
sensitivity [42, 57]. If there was a weakness to be found in the Morino et al. [42, 57] theory and
findings, it was that rodent models were used (fat-fed and knock-out) which demonstrated very
limited ways that IR progresses. Also, serine-kinase seemed to be a secondary mechanism,
possibly second to FA-CoA or DAG (which activates PKC isoforms). Finally, the question of
whether or not it is increased IMCT that leads to IR, or decreased use of IMCT still remains.
Also, the accumulation byproducts from the altered metabolism is possibly to blame.
Additionally, very little has mentioned of the relationships between lipotoxicity and oxidative
stress, which are also likely culprits in this scenario.
Previous to Morino’s work, Segall, et al. [102] also looked into the idea that elevated FFA
led to IR. This study suggested that prolonged β-cell exposure to FFA caused decreased
mitochondrial membrane potential and increased uncoupling proteins, which led to opening of
K+ sensitive ATP channels and impairment of glucose stimulated insulin secretion [102].
Although this in vitro study clearly indicated that β-cell mitochondrial membrane potential was
disrupted by fat, in vitro studies lack do not account for complex intra-and intercellular responses
that occur in vivo, and also only look at one aspect at a time. It is much more likely that not one
single aspect leads to IR and diabetes, and as such, future studies should focus on a balance of
beneficial and deleterious factors affecting metabolism, including pro and antioxidants, glucoand lipotoxicity, and exercise.
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ROS from NADPH
NADPH oxidase is a known source for ROS production in vasculature and kidney in

diabetes. NADPH is found in neutrophils that produce ROS to aid in nonspecific host defense.
They are, however, mostly dormant until stimulated by cytokines, high glucose, or
hyperlipidemia [103, 104]. The Li and associates (2003) findings indicated that upregulation of
neutrophilic NADPH ROS production may have led to oxidative stress via increased angiotensin
II labeling. This stress was blunted by type 1 receptor antagonists and PKC (used in GLUT4
translocation) inhibitors, implicating this family of kinases in the regulation of hyperglycemiainduced NADPH oxidase activity. However, much of the Li and associates (2003) conclusions
were extrapolations based on findings from other studies, and this production of ROS was not
necessarily diabetes specific. This production has also been found in healthy individuals, and is
likely to aid in more than just non-specific immune functions. Further research is needed to
determine if the H2O2 production in neutrophils might also play a role in stimulating the body’s
endogenous antioxidant response to an imminent increase in ROS production.


Additional ROS Sources
Elevated ROS not only affects kidney and mitochondria as discussed above, but also several

other structures including the endoplasmic reticulum (ER). In order for the ER to protect itself,
protein folding in the ER occurs and is termed UPR. UPR has been associated with oxidative
stress, excess energy-substrate utilization and Ca++ loading to name a few [105, 106]. This
folding process (UPR) is a protective mechanism that occurs in order to alleviate ER stress.
However, this process to alleviate ER stress is also associated with increases in ROS and
inflammatory pathways [107-111]. Unfortunately, it was not clearly established if ER stress
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leads to ROS production, or vice versa. Herein potentially lies yet another cycle of ROS
generation likely caused first by increases in NEFA and further exacerbated by ER stress and
UPR for ER protection.


ROS and IR
As seen from the previous studies, ROS, oxidative stress, and metabolism are strongly related

to IR. However, since there is such strong evidence on the effects of oxidative stress and IR,
further exploration of this relationship is warranted.
Insulin resistance is seen not only in muscle, liver and kidney, but also in adipocytes as a
result of increased ROS production. A series of studies illustrated several steps in which ROS
affects IR negatively. For example, [75, 112] showed that adipocytes became insulin resistant
with exposure to glucocorticoids or tumor necrosis factor alpha (TNFα) in vitro. Also, ROS
interfered with insulin signaling at various levels and were able to inhibit the translocation of
GLUT4 in the plasma membrane [113]. Glucocorticoids decreased inflammation and helped
regulate glucose metabolism by acting through a nuclear hormone receptor. TNFα stimulated
inflammatory agents and signals via a cell-surface cytokine receptor. In the above studies, both
TNFα and glucocorticoids were shown to stimulate JNK [a member of the MAPK (mitogenactivated protein kinase) superfamily], which helped mediate ROS. Also, adipocytes were treated
with TNFα and dexamethasone in order to induce insulin resistance in mice. Thirty-four upregulated genes were common to both treatments, and 18% of those were ROS related. Gene set
enrichment analysis (GSEA) indicated that ROS-related genes were the highest scoring for both
treatments, and the ONLY high-scoring set common to both treatments. DCF (oxidized dye) was
more oxidized with treatments, and oxidation occurred before IR. Protein carbonyl elevation was
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also noted, which may have helped explain the development of IR via oxidative damage. After
treatment, IR was then reduced in two different ways: 1) by washing out the agents used (TNFα
and glucocorticoids), and by reduction of ROS with addition of antioxidants NAC and MnTBAP.
By seeing a decrease in IR with the specific reduction of ROS, it was not unreasonable to assume
that ROS had a causal role in the development of IR. Also, when TZD and MnTBAP were given
to leptin deficient ob/ob mice, it resulted in a dose-dependant decrease in oxidative stress and IR.
In spite of the strong evidence that this studies presented, the results were limited to in vitro
experiments and observations made in mice engineered to display IR from a specific pathway,
rather than from an unknown number of mechanisms like in humans. Also, IR was estimated
using OGTT and not directly measured. This actually did not show IR as much as it did a
reduction of glucose tolerance- a downstream outcome from IR.
Traditionally, T2D and IR have largely been associated with obesity and hyperglycemia.
However, IR develops before a decline in glucose regulation, so it is important to focus on early
stages of IR and what may cause this. There have been several studies that looked at early IR as
it was related to oxidative stress, and evidence indicated that elevated ROS was a precursor to
hyperglycemia, especially in obese subjects [90]. Further research into this phenomenon
indicated that elevated free-fatty acid (FFA) was a likely cause [114-118]. These studies showed
that FFA inhibited insulin-stimulated glucose transport. Furthermore, FFA and their metabolites
interfered with transcription factors for lipid and carbohydrate metabolism by elevating the
intramitochondrial acetyl CoA/CoA and NADH/NAD+ ratios with subsequent inactivation of
pyruvate dehydrogenase. This inactivation then caused citrate concentrations to increase, which
led to inhibition of phosphofructokinase and subsequent increases in intracellular G-6-P
concentration, which may have inhibited hexokinase activity resulting in increased intracellular
121

glucose concentrations and reductions in muscle glucose uptake. This was based on a theoretical
construct developed from correlational studies with quantification of FFA and oxidized
glutathione and MDA, which has since been shown to be an unreliable and dirty measurement of
lipid oxidation. It was unclear whether FFA increases oxidative stress, or impairs endogenous
antioxidant capacity because specific mechanisms have not been fully recognized. It is entirely
possible that inflammation intermediates could be the mechanistic trigger for FFA and ROS
development.


Oxidative Damage
Elevated ROS causes damage, and that damage can have large negative effects, such as DNA

mutation, IR, metabolic dysfunction, and diabetes to name a few. However, the loss of function
of the damaged cell may not be the only problem associated with oxidative stress. The markers
of damage may also have further deleterious effects on human physiology other than simply a
marker of immediate damage from ROS.
Various consequences of oxidative stress in diabetic subjects also involve accumulation of
damage markers from either lipid or protein. Common sites of lipid peroxidation are cellular
membranes. As such, damage is typically done with a slightly more stable oxidants, like H2O2,
which are more permeable to the cell membrane and can travel from the site of production.
Recently, accumulation of 4-hydroxy-nonenal (4-HNE) has become a premier marker of lipid
peroxidation. However the role of 4-HNE in diabetes is not yet clear, but their presence are clear
indications of oxidative damage [119]. Traverso et al. [119] were able to show that certain
isoprostanes (4-HNE, MDA) specifically from liver were the direct result of damage from ROS
in diabetic rats as compared to control. Although the in vivo methods clearly indicated that
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isoprostanes were elevated with increased ROS, it was unclear whether the isoprostanes increase
was due to increased in production, or decreased removal. More importantly it could be
determined if an increase in ROS production led to this isoprostane increase, or a reduction in
antioxidant quantity or activity. Furthermore, in the 8-weeks that the rats were engineered, the
experimental rats were not able to gain as much weight as the control rats. Body weight
differences may have interfered with metabolic activity and confound the results of this
experiment.
Other markers of oxidative stress which can help determine protein peroxidation are
advanced oxidation protein products, sulphydryl groups, or uncoupling proteins and protein
carbonyls. Since these proteins are damaged inside the cells (DNA, organelles, etc) damage is
either occurring from fast-reacting SO and hydroxyl, or from more stable oxidants that can pass
through the cell membrane, like H2O2. These types of markers have been measured easily in both
plasma and urine, but greater sensitivity has been seen in plasma [120]. Negative effects of
uncouple protein-2 (UCP2) activity, protein carbonyls, and other markers of protein oxidation
have been shown to increase SO formation in T2D [51]. These markers were negative regulators
of insulin secretion in isolated mitochondria and intact cells, and were up-regulated in ob/ob and
diabetic mice. Unfortunately these studies that indicated the specific functions of such damaged
proteins were done in knockout mice, which lack the complexity of the natural state of T2D.
Furthermore, when further studies were done in vivo, unnaturally high SO levels were used to
achieve this protein damage. Hence, it is not completely clear how these damage markers may
affect the progression of IR and diabetes, or if it was just that damage occurs that is the sole
detriment.
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Antioxidant Activity
There is a relationship between elevated ROS levels and oxidative damage in vitro, in

animals, and in humans. It has also been shown that increases antioxidant levels helped protect
cells from oxidative damage and helped reduce ROS levels. However, much focus has been
placed on increased ROS levels as the cause of the oxidative damage. It is not beyond reason
that a decrease in antioxidant concentration or activity may be at least partially responsible for
the ROS elevation and oxidative damage. With so much focus on oxidative damage and ROS
production, relatively little is known about the possible changes in endogenous antioxidant
function as a possible cause for the increased oxidative damage, rather than increased ROS
production. It has been shown that reducing L-arginine via alloxan treatment in rats reduced
GSH, SOD, and CAT activity in rats while also increasing MDA (a common marker of lipid
peroxidation) levels [121]. Interestingly, L-arginine is a pre-cursor to nitric oxide (NO) which
can potentially be a powerful oxidant in addition to a vasodilator. It has been shown that NO was
reduced in diabetic subjects, and was related to a decline in gastric emptying and reduced NO
availability [122]. Hence, this potential potent oxidant also seemed to serve a purpose in the
function and regulation not only as a vasodilator, but of antioxidant activity as well. However,
these findings showed the ill-effects of alloxan rather than specifically showing the affects of Larginine reductions in rats while ignoring the possible side-effects of drug administration. Also,
supplemental L-arginine administration affected pro and antioxidant status rather than normal
physiologic levels of endogenous L-arginine in vivo. Studies should be conducted to better
determine optimal physiologic levels of L-arginine rather than supplementing with large doses.
Antioxidant intervention may help aid the endogenous antioxidant defenses against ROS and
oxidative stress. However, with so many kinds of antioxidant supplements, it is difficult to know
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exactly what effect individual antioxidants may have, and in what concentration they may be
beneficial. Antioxidant supplementation has been shown to aid in overall antioxidant activity in
T2D as related to ROS production. More specifically, high doses of grape seed extract for four
weeks has been shown to lower inflammation markers and glycaemia, a marker of oxidative
stress, in people with T2D [123]. This strongly implied that the deleterious oxidizing effects of
ROS were lowered with antioxidants. However it is not safe to assume that oral administration of
high-doses would act the same way as endogenous antioxidants. Also, there was no target
specified nor was there a direct measure of ROS. Therefore, this study showed a strong
association of oral antioxidant intervention and a decline in one marker of oxidation. It is not
clear if this was because the grape seed extract acts to neutralize ROS, prevent its formation, or
assist in the function of endogenous antioxidants. Also, these results are controversial because
they are not uniformly supported by other studies performing antioxidant interventions.
One study that did help support these findings showed that short term antioxidant
supplementation helped moderately improve IR [124]. However, as with many other studies
looking at antioxidant supplementation, Vincent et al. [124] did not directly measure ROS
production, or oxidative damage, nor were there any mechanisms shown that affected IR. In
addition, since this was a human study, little control over confounding factors like diet and
activity were in place. Even though, considering both this and the Kar et al. [123] study, it is
likely that antioxidants can improve insulin sensitivity by reducing oxidative damage. More
studies need to be conducted examining the balance of pro and antioxidants, and how shifts in
this balance may lead to oxidative stress and IR.
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 Summary
Oxidative stress, related defects in oxidative phosphorylation machinery, and mitochondrial
beta-oxidation lead to excess accumulation of intracellular triglycerides in muscle and liver, and
to subsequent insulin resistance [96]. In addition, beta-oxidation of long-chain FFA provides
energy for cardiac and skeletal muscle, however increased FFA is also associated with
lipotoxicity and muscular IR and abnormal beta cell function at least ten years prior to the
diagnosis of T2D, and are also increased by oxidative stress [55]. Metabolic byproducts IMCT
including fatty acyl CoAs, diacylglycerol (DAG), or ceramides are all thought to be detrimental
to the sensitivity of insulin [37, 117, 125]. In addition to lipotoxicity, ROS and IR become
elevated through increased chronic levels of blood-glucose, leading to glucotoxicity [96].
There is very little evidence indicating how and why elevated ROS is produced in diabetes,
or how it acts to increase IR. We know that changes in metabolic function (via hyperglycemia or
hyperlipidemia) can adversely affect the body’s ability to handle increased ROS production
leading to oxidative stress. However it is unclear whether this is due to increased ROS
production or decreased level and/or activity of endogenous antioxidants.
In reality, the increases in ROS and oxidative damage are closely related to circulating
cytokines and long-chain fatty acid. What we do NOT know is what the initial cause of this
deleterious cycle is. One novel idea is an increase in ROS production leads to mitochondrial
damage. This damage then triggers the body to protect itself against further oxidative damage by
down-regulating mitochondrial DNA expression to reduce metabolism, thereby reducing the
production of ROS. However, this theoretical protective measure is not without consequence.
The decreased mitochondrial activity (or mitochondrial dysfunction) inhibits the muscle from
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utilizing the IMCT causing a back-up of both circulating long-chain fatty acid and glucose in the
blood and in the electron transport chain, leading to proton leaking and further oxidative damage
[126]. These in turn further inhibit the cell’s ability to respond to insulin, leading to T2D.


Future Research
Given the current literature and its lack of in vivo human studies, future studies should

include aspects of diabetes like chronic blood-glucose and FFA regulation and how they may be
related to ROS and antioxidant concentrations, and how that balance affects oxidative damage
markers and IR. For example, higher Hba1c is due to poor glucose regulation, which may lead to
glucose toxicity and glucose auto-oxidation causing increased ROS, higher islet apoptotic rates,
and reduced insulin secretion. These can easily be estimated using an at-home Hba1c test,
measuring pro and antioxidants in plasma as well as damage marker, and then determining if a
shift in the pro and antioxidant balance that leads to oxidative stress is related to a decline in
OGTT.
Influences of physical activity on oxidative stress in resting diabetes metabolism


Acute Exercise and Oxidative Stress
Acute exercise increases oxidative stress in diabetics and healthy individuals. Specifically,

diabetes induces oxidative stress and impairs myocardial HSP60 expression in rats, thereby
increasing oxidative damage [127]. With acute exercise, we see sharp increases in ROS
production and subsequent decreases in antioxidants, theoretically to offset the increase in ROS.


FFA Lipolysis
As previously indicated, studies show that increased insulin sensitivity and improved fatty-

acid oxidation are related to lower oxidative stress at rest. Triglyceride clearance is improved
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with exercise, leading to lower oxidative stress and improved insulin sensitivity in several ways.
First, exercise stimulates increases in endogenous antioxidant enzyme activity. Second, it
improves blood glucose clearance via enhanced GLUT 4 translocation and protein content, as
well as enhanced insulin-insulin receptor binding and post-receptor signaling. Third, exercise
also improves blood triglyceride clearance via a reduction in chylomicron-triglyceride half-life
and enhanced lipoprotein lipase activity [128], [129].
What remains unclear however is if it is the oxidative stress that leads to decreased fatty acid
oxidation, or vice versa. Indications are that some of these discrepancies could be due to the
different stages of the disease. For example, some preliminary studies indicated that early stage
T2D patients displayed impaired lipolysis and beta oxidation over controls [30, 32, 130, 131]. In
what seems like contradictory findings, a more recent study examining long-term diagnosed T2D
patients showed that fasting whole-body fat oxidation rates are elevated in long-term diagnosed
T2D patients as compared to recently diagnosed T2D patients from his previous studies [29]. In
this study, increased fat oxidation is attributed to greater plasma FEFA appearance rates,
elevated plasma FEFA availability, and increased plasma NEFA disappearance and oxidation
rates. Since insulin inhibits adipose tissue lipolysis, long-term diabetics that that lack
hyperinsulinaemia do not display this inhibition, and thus have increased fat oxidation.
Furthermore, hyperglycaemia in long-standing T2D patients were associated with increased
plasma glucose appearance and disappearance rates, but were not accompanied by elevated
carbohydrate oxidation rates. The moderate intensity exercise program showed improved plasma
glucose disposal [29]. This study however, only showed the effects of acute, low-intensity
aerobic exercise on sedentary diabetics. Another potential problem with this study was the
passive recovery, which allowed metabolic byproducts to stagnate in the muscle because of
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decreased muscle-pump action forcing blood to wash them away. Furthermore, researchers
attempted to equalize exercise work-loads, relative workloads were 63% and 54% for T2D and
control groups respectively. It is possible that the changes in this study may have been due to a
higher relative work-load in the T2D group.


Antioxidant Activity
In addition to improved FFA lipolysis, it has been well established that as little as a single

bout of aerobic exercise can improve insulin sensitivity. However, a direct link between exercise,
oxidative stress, and improved insulin sensitivity has not yet been clearly established. One
possible explanation is that though exercise has been shown to increase ROS production, a
possible simultaneous stimulation of endogenous antioxidants may help combat the ROS
production and have a compensatory effect on IR above the aforementioned increases in lipolysis
[132, 133].
The development of oxidative stress comes about from either, 1) an increase in the
production of ROS or NOS, or 2) decreased availability/effectiveness of endogenous
antioxidants to combat the oxidative damage. The latter has gained increasing attention in recent
years. Studies showed that a single bout of aerobic exercise can increase SOD activity in T2D
and not in control groups [134]. GPx was also significantly increased in T2D groups, but not as
much as Mn-SOD, but was increased more in T2D patients with diabetic complications
following a bout of exercise. Unfortunately, the authors of this study failed to indicate how long
after exercise the blood draws were taken. It is entirely possible that if too much time had
elapsed, a more effective circulatory system in healthy controls subjects may have been able to
wash away SOD and GPx markers and filter them through the liver faster than the T2D group. In
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addition, this was a single bout of aerobic exercise, which we know to also increase ROS
measures as well. However the authors did not examine ROS markers, and thus cannot indicate
with any authority if an increase in ROS stimulated antioxidant production, or if it was another
mechanism of mechanical contraction.


Chronic Exercise and Oxidative Stress
More importantly than how the body reacts to a single bout of exercise is how well it adapts

to the introduction of a continued exercise training protocol to help counter the effects of
oxidative stress and IR in T2D. In exercise intervention studies, we see improvements in diabetes
control and lower oxidative stress. One such study showed that exercise had beneficial effects
on glycaemic control, insulin resistance, cardiovascular risk, oxidative stress-defense parameters
in overweight and obese type 2 diabetics [135]. More specifically, after three and six months of
aerobic exercise training, plasma MDA significantly decreased and CAT significantly increased
in T2D males. In his study, Lazarevic followed a group of sedentary diabetic males in an aerobic
exercise protocol for six months. Since aerobic exercise has been shown to reduce IR acutely,
without a follow-up test visit several days after ending training, it was not possible to determine
if aerobic exercise training had an effect on antioxidants and oxidative stress, or if it was just the
short-lived effects of an acute bout of aerobic exercise. In his report, there were also no
explanations as to how these adaptations came about. Further explanation is needed on what
happens to elicit such changes.


FFA Lipolysis
Recently, we have seen exercise described as not only a model for oxidative stress, but also

as an important tool in diabetes management [136]. Exercise training aids in redistributing body
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fat and lipid balance, but mechanisms are yet to be defined as to how this affects IR and
oxidative stress. In a recent review, Muoio suggested that one possibility was that exercise
training leads to a shift from white to red (oxidative) muscle fibers, leading to possible increases
in fat oxidation [126].
There is a well-established link between oxidative stress and the ability to efficiently
metabolize fats. However, since the data on the effects of exercise training on fasting oxidative
stress is lacking, some attention should be paid to its effects on fat metabolism. As with acute
exercise, conflicting findings on the effects of exercise training on FFA lipolysis. For example,
there have been studies that indicate aerobic training increases lipolytic rate and insulin
sensitivity [137], though some have suggested these adaptations are reversed in as little as four
days [138]. These indications are not consistent, however. These findings may have been
influenced by postprandial blood sampling, and showed no changes in lipolytic rate after an
overnight fast without weight loss [36]. One possible explanation for the rapid decline from the
benefits of exercise is that in these studies, they were strictly aerobic in nature, which does not
lead itself to muscle mass gains. These possible changes in fatty acid metabolism, though shortlived, may have contributed to lower oxidative stress at rest within a few days of exercise.
Supporting the idea that exercise training enhances lipid metabolism was a recent study by
Bordenave. In this study, people with T2D were exercise trained twice a week for ten weeks on
cycle ergometers at a level that was optimal for lipid oxidation (LIPOXmax) twice a week on a
cycle ergometer. What was found was increased lipid oxidation during exercise after training and
improved mitochondrial respiration as measured by pyruvate and citrate synthase activity in
muscle biopsies [139]. Circulating NEFA was not seen to decline, indicating that the increased
fat oxidation was primarily from IMCT. However, there were no significant changes seen in
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blood-glucose, glycated hemoglobin, or glucose oxidation. Given that the intervention was only
ten weeks, a significant reduction in Hba1c would not be expected, as it measures the preceding
12 weeks of glycation. A longer training intervention, followed by a six month follow-up may
have shown significant decreases in Hba1c levels. Also, the training stimulus may not have been
adequate in that there was a lack of progression throughout the ten weeks of aerobic training.


Antioxidant Activity and Exercise
It is clear that exercise has impacts on oxidative stress and insulin resistance, but very little

has been offered to explain how this takes place. With diabetes, we see elevated oxidative stress
and damage, mostly attributed to increased ROS production. However, exercise also increases
ROS, yet also seems to have a lowering effect on oxidative damage. One possible explanation is
that exercise helps boost the body’s endogenous antioxidant defense system. Recent evidence
suggested that aerobic exercise training increased antioxidant capacity in diabetic rats [140].
This increased antioxidant capacity (specifically thioredoxin-1, or TRX-1 in the brain) led to an
enhanced ability to offset ROS and NOS and possible reduction in oxidative stress. However,
with animal studies, the effects may not translate to human models. Another aspect not
examined was how training enhanced antioxidant status. One possible explanation is that
endurance training may have helped up-regulate antioxidant mRNA and decrease lipid
peroxidation. Further illustrating how exercise helps the body protect itself via enhanced antioxidant capacity was a study by Gul and Laaksonen. In his study, Gul showed that after eight
weeks of aerobic treadmill exercise with 10% incline, rats exhibited increased aerobic endurance,
upregulated GPx and decreased TBARS in both muscle and kidney [141]. In addition, there was
better control over hyperglycemia in T2D rats after training. It is unclear if the reduction in
hyperglycemia was a direct result of decreased oxidative damage (TBARS) or increased GPx
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regulation, or even if the up-regulation of GPx was responsible for the decrease in oxidative
damage. However, it is likely that a better-trained antioxidant system was better able to handle
ROS production, and thereby reduce oxidative damage and aid in glucose regulation.
Not only does exercises seem to boost endogenous antioxidants, but aerobic exercise training
can have a reducing effect on the accumulation of oxidative stress markers [142]. In his study,
Ristow showed that in as little as four weeks of aerobic and circuit training, significant
reductions in ROS measures and TBARS were seen as well as increases in antioxidants and
glucose infusion rates via insulin clamp. His implication was that the increases in ROS
production from exercise had a beneficial effect on insulin sensitivity and glucose clearance.
However, with the increased antioxidant levels at rest from this study, it is more likely that
exercise produced ROS production challenged the antioxidant system to improve, causing a shift
in the endogenous antioxidant defense status at rest [132, 133], which may have been partially
responsible for the reduction TBARS and IR. For example, regular exercise has long been
shown to strengthen antioxidant defenses in non-diabetic animal models and may have been
responsible for decreased resting and acute exercise-induced oxidative stress as a result [132,
133, 143-146]. In addition to his unorthodox conclusions, there was also no mention of plasma
volume increases due to exercise training. Some of these adaptations seen may have been
affected by the increased plasma volume often associated with chronic exercise training or from
decreased plasma volume from an acute bout of exercise. Also, TBARS may not have been the
ideal marker of damage, especially with exercise training which utilizes protein (muscle) so
extensively.
Several studies have been conducted on the effects of exercise on oxidative stress, however
most of them have examined the effects of acute exercise rather than chronic. Even with some of
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the exercise training studies performed, it has been difficult to separate out the physiologic
changes may be from acute vs. chronic exercise. However, Chang et al. [147]has shown the
effects of both acute and chronic aerobic exercise on oxidative stress markers. In this eight week
aerobic treadmill study, these researchers showed significantly improved antioxidant defense
function of Mn-SOD, GPx, and GSH in obese Zucker rats [147]. In this study, to account for
acute vs. chronic exercise effects, rats were killed 48 hours after last exercise session thus
reducing the acute effects. No change in fasting glucose was seen between trained and untrained
rats, however Mn-SOD activity was significantly increased in trained vs. un-trained rats. Also,
impaired GPx and GSH in pre-trained obese rats significantly improved with training. Chang
also noted increased mRNA levels of both Mn-SOD, and GPx. It is quite interesting to see that
the up-regulated antioxidant system remained that way 48 hours post exercise, however with no
markers of damage taken or measures of IR, it is unclear if these antioxidant changes had any
diminishing effects on oxidative damage or IR.
The balance between pro and antioxidants is important to maintain proper cellular health. We
have seen that exercise (both acute and chronic) has positive effects on endogenous antioxidant
status [142, 147], however little is known about the effects of antioxidant supplementation on
oxidative stress with exercise in T2D. In the exercise training study by Ristow mentioned earlier,
he also examined the effects of supplementation with oral antioxidants (vitamin C and E) after
exercise training. Though it would seem that more is better, the positive changes seen from his
exercise intervention (decreased TBARS and ROS, and increased glucose infusion rates) were
nullified with oral antioxidant supplementation. The explanation he offered was that the ROS
produced from exercise had beneficial effects on glucose tolerance. However, it is likely that oral
supplementation of antioxidants (as with amino acids) may have inhibited/limited the body’s
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ability to produce endogenous antioxidants on its own. These oral antioxidants may actually
blunt the beneficial effects of SOD, CAT, or GPx. However, since his study did not measure
levels of these endogenous antioxidants, any speculation on this cannot be verified.


Summary
Acute and chronic exercise has been shown to decrease oxidative stress by increasing

endogenous antioxidant production and activity leading to an overall decrease in oxidative
damage. These adaptations may precede the reduced IR that also accompanies exercise. The
decreased IR may be due to lower blood-glucose from insulin-independent glucose transport, or
from possible enhanced, or complete, metabolism of lipid, which in turn can also decrease
fasting oxidative stress. There seems to be no starting point in the deleterious chain that leads to
IR and diabetes, however aerobic exercise seems to intervene on several levels to help better
regulate glucose and fat metabolism, and lower IR and oxidative stress.


Future Considerations
Little is known of the effects of exercise interventions on fasting oxidative stress as it relates

to lipid and glucose metabolism and insulin sensitivity. Even less is known of the effects of
resistance training on oxidative stress or glucose tolerance and IR. Future research is needed to
determine if continuous resistance training can aid in restoring redox balance in diabetes and pre
diabetes. There have been several studies that have shown increases in glucose tolerance and
reductions in insulin resistance with aerobic training, however these effects are quickly lost after
as little as three days without exercise. One possible explanation is that aerobic training does not
increase muscle mass, making any possible changes seen based on long-term recovery kinetics
rather than longer-lasting metabolic adaptations. It is possible that the increased muscle mass that
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accompanies resistance training may allow such beneficial adaptations to remain longer after
cessation of training.
Offspring of diabetics have been targeted as a highly likely group to develop T2D if glucose
tolerance is low. It is critical to be able to identify and target specific mechanisms which would
reduce development of T2D. With the effects of aerobic training on glucose tolerance being
short-lived, perhaps incorporating resistance into an intervention will yield longer-lasting results.
Since both glucotoxicity and lipotoxicity lead to diabetes, any exercise interventions should
include measures of glycated hemoglobin and circulating NEFA, and determine whether
resistance training has an effect on these measures as well as resting glucose and fat oxidation
and oxidative stress.
Summary
T2D has been identified principally as a metabolic disease. As such, research has focused in
large part on metabolic mechanisms that affect IR and glucose uptake. Among these have been
glucose toxicity, lipotoxicity, inflammation and oxidative stress. Oxidative stress is of particular
interest in the study of T2D because it seems to be related to almost every mechanism of T2D
development.
For example, oxidative stress, along with related defects in oxidative phosphorylation
machinery, and mitochondrial beta-oxidation lead to excess accumulation of IMCT in muscle
and liver, and to subsequent insulin resistance [96]. However, the scope of much of the existing
research has been too limited to get a clear picture of what is really happening to the altered
metabolism of diabetics. Elevated IMCT- whose metabolic byproducts, including fatty acyl
CoAs, diacylglycerol (DAG), or ceramides are all thought to be detrimental to the sensitivity of
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insulin in diabetics has been blamed for IR [37, 117, 125], yet highly-trained aerobic athletes
also show increased IMCT, but do NOT exhibit the oxidative stress or insulin resistance.
This leads to the supposition that it is not the retention of IMCT that causes these problems,
but perhaps a problem with their use. In addition, beta-oxidation of long-chain FFA provides
energy for cardiac and skeletal muscle. However, increased FFA is also associated with
lipotoxicity and muscular IR and abnormal beta cell function at least ten years prior to the
diagnosis of T2D, and are also increased by oxidative stress [55]. In the early stages of T2D,
higher than normal insulin levels have an inhibitory effect on lipolysis, but as the disease
progresses, the drop in insulin results in beta oxidation no longer being suppressed [114, 125].
What is evident from existing research is not what mechanisms cause the development of IR, or
even what causes oxidative stress to increase so much as it reveals a lack of understanding of the
diabetic model in its complexity.
In addition to lipotoxicity, ROS and IR become elevated through increased chronic levels of
blood-glucose, leading to glucotoxicity [96]. This increase leads to glucose auto-oxidation,
glucotoxicity, damaged pancreatic islet cells, and ultimately the decrease of insulin production.
However, it is obvious that since these elevations affect insulin production, they also affect
lipolysis, IMCT formation and breakdown, and ROS production not only as a direct result of the
glucose elevation, but also from some of the lipid-induced processes discussed above. Clearly,
manipulation of one or more aspects of diabetes metabolism has effects on outcome measures
such as IR and glucose tolerance. These systems are part of an ongoing cycle that play upon each
other to exacerbate the breakdown of T2D metabolism. These kinds of interactions of the
different systems affecting diabetes metabolism and IR have not been studied as systems
working together and against each other simultaneously, and as a result are not fully understood.
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There is very little evidence indicating how and why ROS is elevated in diabetes, or how it
acts to increase IR. It has been suggested that changes in metabolic function (via hyperglycemia
or hyperlipidemia) can adversely affect the body’s ability to handle increased ROS production
leading to oxidative stress. However because of a lack of agreement in the literature, it is unclear
whether this is due to increased ROS production or decreased level, changes in chronic
inflammation, and/or activity of endogenous antioxidants. ROS overproduction is blamed for the
production of oxidative stress, however it is not possible to draw these kinds of conclusions
unless other aspects are also measured simultaneously, including antioxidant
bioavailability/activity and efficient repair of oxidative damage. So far, there have been no
studies that have conducted this kind of comprehensive examination of the oxidative model in
T2D.
It has been shown that increases in ROS and oxidative damage are closely related not only to
gluco- and lipotocicity, but also increased circulating cytokines. However, since no initial cause
has been identified, there is no known starting point for this cycle. One novel idea used by
several researchers is that an increase in ROS production leads to mitochondrial damage. This
damage then triggers the body to protect itself against further oxidative damage by downregulating mitochondrial DNA expression to reduce metabolism, thereby reducing the
production of ROS. However, this theoretical protective measure is not without consequence.
The decreased mitochondrial activity (or mitochondrial dysfunction) inhibits the muscle from
utilizing the IMCT completely causing increasing levels of IMCT, and a back-up of both
circulating long-chain fatty acid and glucose in the blood and in the electron transport chain,
leading to proton leaking and further oxidative damage [126]. These in turn further inhibit the
cell’s ability to respond to insulin, leading to yet more increases of insulin production, followed
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by further decreases in lipolysis and ultimately the progression of T2D. Interestingly, this
concept is directly and indirectly connected with other prevailing theories IR development and
oxidative stress in that it leads to a cycle whereby increased ROS production leads to oxidative
stress, IR, elevated FFA and IMCT, glucotoxicity, and likely to inflammation. However since
this is cycle is a prevailing theme in T2D research, there is still not clear starting point to this
process, nor is there a good understanding of how these connected factors influence each other.


Exercise and T2D
Acute and chronic exercise has been shown to decrease oxidative stress by increasing

endogenous antioxidant production and activity [148] leading to an overall decrease in oxidative
damage. These adaptations may precede the reduced IR that also accompanies exercise. The
decreased IR may be due to lower blood-glucose from insulin-independent glucose transport, or
from possible enhanced, or complete metabolism of lipid, which in turn can also decrease fasting
oxidative stress. There seems to be no starting point in the deleterious chain that leads to IR and
diabetes, however both strength and aerobic exercise seem to intervene on several levels to help
better regulate glucose and fat metabolism, and lower IR and oxidative stress. It is difficult to say
with any authority exactly HOW exercise affects the diabetic model since there is no universal
testing model in place. So far, much of what has been done has a small focus and ignores much
of the confounding factors that ALSO affect the outcome measures being examined. For
example, looking at decreases in oxidative stress after exercise training is interesting, but is that a
result of the exercise, of lower triglycerides, of non-insulin stimulated glucose uptake, metabolic
increases both during and after exercise (EPOC), etc.? The scales are tipped towards reduced IR
and improved glucose uptake, but by ignoring other aspects of the T2D model, questions like
these cannot be answered.
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Future Research
Given the current literature and its lack of in vivo human studies, future studies should

include aspects of diabetes like chronic blood-glucose and FFA regulation and how they may be
related to ROS and antioxidant concentrations, and how that balance affects oxidative damage
markers and IR. For example, higher Hba1c is due to poor glucose regulation, which may lead to
glucose toxicity and glucose auto-oxidation causing increased ROS, higher islet apoptotic rates,
and reduced insulin secretion. These can easily be estimated using an at-home Hba1c test,
measuring pro- and antioxidants in plasma as well as damage markers, and then determining if a
shift in the pro and antioxidant balance that leads to oxidative stress is related to a decline in
OGTT. These kinds of studies are lacking in the current literature. Much of the research done is
extremely narrow in focus when in fact the problem if IR in T2D is broad and complex.
Little is known of the effects of exercise interventions on fasting oxidative stress as it relates
to lipid and glucose metabolism and insulin sensitivity. Even less is known of the effects of
resistance training on oxidative stress or glucose tolerance and IR. Future research is needed to
determine if continuous resistance training can aid in restoring redox balance in diabetes and pre
diabetes. Several studies have shown increases in glucose tolerance and reductions in insulin
resistance with aerobic training, however these effects are quickly lost after as little as three days
without exercise. One possible explanation is that aerobic training does not increase muscle
mass, making any possible changes seen based on long-term recovery kinetics rather than longerlasting metabolic adaptations. It is possible that the increased muscle mass that accompanies
resistance training may allow such beneficial adaptations to remain longer after cessation of
training.
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Furthermore, offspring of diabetics have been targeted as a highly likely group to develop
T2D if glucose tolerance is low. It is critical to be able to identify and target specific mechanisms
in which these chances are decreased. With the effects of aerobic training on glucose tolerance
being short-lived, perhaps incorporating resistance into an intervention will yield longer-lasting
results. Since both glucotoxicity and lipotoxicity lead to diabetes, any exercise interventions
should include measures of glycated hemoglobin and circulating NEFA, and determine if
resistance training has an effect on these measures as well as resting glucose and fat oxidation
and oxidative stress.
All things considered, there is much research still needed to determine how ROS affects the
development and progression of T2D, and how different modes of exercise can prevent and even
alleviate some of the problems leading to its continued progression. However, to date, most of
the research on ROS, lipotoxicity, glucotoxicity, antioxidants, and inflammation on T2D
outcomes have been extremely narrow in focus. There is no uniform method for testing the
effects of manipulating ANY of these variables in IR or glucose tolerance. Since each of these
variables interacts with one another, ignoring these interactions prohibits a true understanding of
the complexity of this disease and negates much of the conclusions made by recent narrowfocused studies. Before any real understanding can be reached, a model for testing should be
developed that incorporates a balance of positive and negative interactions affecting the
development and progression of T2D. For example, this model should include both lipo- and
glucotoxicity models, and examine the balance of ROS/NOS production and how endogenous
antioxidants are able/unable to defend the body against a shift towards oxidative stress as
measured by oxidative damage. With this, we can determine what magnitude of redox regulation
shift is required to cause damage. Furthermore, oxidative damage markers alone are insufficient
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to elucidate why oxidative damage may be developing in T2D. Therefore, a balance of pro- and
antioxidants should be assessed to better understand whether those with T2D display overabundant ROS production, or a lack of endogenous antioxidants to help protect the system from
such damage. Lastly, this balance model of the oxidative damage system (pro- and antioxidants
in addition to damage markers) are only an outcome of a physiologic mal-adaptation that seems
to develop long before increased oxidative damage occurs, therefore factors such as
glucotoxicity, lipotoxicity, and chronic inflammation should be examined those displaying the
earliest signs of metabolic dysfunction, such as FH+.
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APPENDIX II: EXERCISE QUESTIONAIRE
Name: _______________________ Date: __________________
1) In the last 3 months, how many times each week have you:
Lifted weights: _______

Done cardio/aerobic workouts: __________ been highly

active:______
2) In a given week, how many hours do you spend exercising? ___________
3) Of those exercises, how much time do you spent performing resistance?
____________________ What type? _______________________
4) How much time do you spend performing aerobic/cardiovascular training?
5) _____________ What type? _______________________________________
6)

Do you take medications on a regular basis? Y / N If so, what are they?

______________________________________________________________________________
7) Do you have diabetes or pre-diabetes?
8) Does anyone in your family have diabetes or pre-diabetes?
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